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Summary
The non-steroidal anti-inflammatory drugs (NSAIDs) are being 
promoted for use as postoperative analgesics, and diclofenac is 
already used widely for that purpose. Ketorolac is a new drug and 
early reports have indicated that it may be useful after surgery. The 
advantages claimed for these drugs are that they are effective 
analgesics which do not produce sedation, respiratory or 
gastrointestinal depression, or dependence. Unfortunately, NSAIDs do 
have important side-effects because they inhibit tissue prostaglandin 
production.
In this thesis, ketorolac is assessed both in comparison with, 
and as an adjunct to, morphine. The effects of ketorolac and 
diclofenac on platelets and the kidneys were studied.
Ketorolac compared with morphine
A double-blind, randomized pilot study compared intramuscular 
ketorolac 30 mg with morphine 10 mg in twenty patients having 
cholecystectomy. Assessments were made immediately after surgery by 
two observers using a simple rating scale. Ketorolac gave analgesia 
equivalent to morphine, and on the basis of these results, a larger 
study was carried out to investigate in detail the use of this new 
NSAID after upper abdominal surgery.
Intramuscular ketorolac 30 mg was compared with morphine sulphate 
lOmg after cholecystectomy in a double-blind, multiple dose, 
randomized study of one hundred patients. Specific assessments of 
pain were made immediately after operation (day 1), and the next 
morning (day 2). Pain intensity (verbal rating scale and visual 
analogue scale) was recorded before injection and then over a six 
hour period. Pain relief was also assessed. Time to commencing
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oral intake and the duration of intravenous fluids were recorded. 
Adverse events were noted. Ketorolac produced significantly less 
analgesia than morphine on day 1 when pain intensity was severe, but 
on day 2 in the presence of moderate pain the two drugs gave a 
similar effect. Repeated intramuscular administration of ketorolac 
did not produce any serious adverse effects. The value of using an 
observer to assess pain in the immediate postoperative period was 
confirmed.
Ketorolac as an adjunct to morphine
The possible opioid sparing effect of ketorolac was investigated 
in seventy-five patients having thoracotomy who were given access to 
intravenous morphine using patient controlled analgesia. In a double­
blind randomized study, patients were given six hourly intramuscular 
injections of ketorolac 30 mg, ketorolac 10 mg, or placebo for forty- 
eight hours from the end of surgery. The consumption of morphine, 
pain scores, sedation, compliance with physiotherapy, and respiratory 
effects were compared between the groups at intervals during the 
study. Ketorolac did not significantly reduce morphine requirements 
or improve pain assessments, but was associated with a higher study 
completion rate, and less sedation and lower arterial blood carbon 
dioxide tensions in the late postoperative period. No serious side- 
effects were encountered with ketorolac.
The effect of ketorolac and diclofenac on platelet function
The effect of ketorolac and diclofenac on platelet function and 
haemostasis was investigated in patients having surgery who had also 
been given prophylactic subcutaneous heparin. Platelet function was 
measured in vivo by the skin bleeding time, and in vitro by whole
-17-
blood platelet aggregation studies. During cholecystectomy, ketorolac 
30 mg intramuscularly prolonged skin bleeding time, although not 
beyond the normal range, and inhibited platelet aggregation within 
one hour of administration, but operative blood loss was not 
increased. Diclofenac 75 mg given during thoracotomy similarly 
prolonged skin bleeding time and reduced platelet aggregation, and 
blood loss was not increased.
The effect of ketorolac in combination with dextran-70 was 
observed in healthy volunteers. Skin bleeding time, platelet 
aggregation, venous blood thromboxane generation, von Willebrand 
factor antigen, factor VIII coagulant activity, and tissue 
plasminogen activator antigen were measured for effects on platelets, 
coagulation factors, and fibrinolysis. Ketorolac markedly reduced 
blood thromboxane generation and inhibited platelet function. Dextran 
reduced factor VIII coagulant activity. There was evidence of a small 
but significant interaction between ketorolac and dextran in reducing 
thromboxane production.
The effect of ketorolac and diclofenac on renal function
The effect of ketorolac on renal function was assessed by 
measurement of plasma urea, creatinine, and electrolytes from the 
subjects enrolled in the cholecystectomy and thoracotomy analgesic 
studies. After cholecystectomy, there were few electrolyte 
abnormalities associated with ketorolac, although in contrast with 
the control group, postoperative decreases in urea and sodium were 
smaller, and potassium and creatinine concentrations did not decrease 
at all. After thoracotomy, plasma urea, creatinine and sodium 
concentrations rose in all groups, although high urea concentrations
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were more common with ketorolac. The main finding after thoracotomy 
was that intramuscular ketorolac was associated with a significant 
rise in plasma potassium concentration.
The effect of intramuscular diclofenac 75 mg twelve hourly on 
renal function was investigated in twenty patients after 
oesophagogastrectomy in a double-blind randomized study. Urinary 6- 
keto-PGFja was used to estimate renal prostacyclin production. 
Assessments were made on the day before surgery and over the next two 
days. In the control group, urinary 6-keto-PGFia rose significantly 
after surgery and peaked in the first twenty four hours. In the 
diclofenac group, renal prostacyclin production did not change. 
Diclofenac was associated with lower urine flow rates and urinary 
sodium and potassium excretion on the first postoperative day, but on 
the next day there was no difference between the groups. The control 
group retained more free water on the first day after operation. One 
patient was withdrawn from the diclofenac group because of concern 
about persistently low urine output.
Other effects
No other serious side-effects were encountered. Muscle pain, 
often apparent after the injection of diclofenac, was not a 
significant problem with ketorolac.
Conclusion
In this thesis, an assessment of the appropriate use of NSAIDs in 
surgical patients is attempted. Ketorolac may be useful for the 
relief of mild to moderate pain, but it is unsuitable for the relief 
of severe discomfort after major surgery. Ketorolac and diclofenac 
inhibit platelet function soon after administration, but this should
-19-
not lead to increased bleeding. Renal prostaglandin production may be 
important in the immediate postoperative period, and because of this 
urinary output and plasma potassium should be monitored when 
ketorolac or diclofenac are used after major surgery.
-20-
CHAPTER 1 
INTRODUCTION
1.1 The problem
Opioids have been the mainstay of post-operative pain relief, but 
there is now a recognition that new drugs are needed to both improve 
analgesia and reduce adverse effects. Increasing use is being made of 
the aspirin-like non-steroidal anti-inflammatory drugs which are 
given before, during, and after surgery. The attraction of these 
drugs is that they may have a significant analgesic action whilst 
avoiding many of the side-effects associated with opioids.
Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) has been the 
most popular of these drugs until now. It is being promoted for post­
operative analgesia and is available as oral, suppository, and 
intramuscular preparations. It is my impression that diclofenac has 
quickly become favoured by clinicians, and is being prescribed widely 
after many operations by anaesthetists and other medical staff.
Ketorolac trometamol (Toradol, Syntex Pharmaceuticals Ltd) is a 
new drug which is soon to be available for general prescription as 
intramuscular, intravenous, and perhaps oral preparations. Early 
clinical studies have indicated that it may be useful as an analgesic 
after surgery, and it is indeed already being promoted in other 
countries for that purpose.
Although many other drugs of this type have been used during 
surgery, it is likely that diclofenac and ketorolac will be the 
agents routinely used by anaesthetists and surgeons because of the 
encouraging clinical trials already published, and the availability 
of parenteral preparations.
However, there are concerns about the rapid introduction of 
ketorolac and diclofenac into anaesthetic and surgical practice 
because of the recognised side-effects of non-steroidal anti-
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inflammatory drugs. The analgesic efficacy of ketorolac needs further 
investigation and the adverse effects of both drugs need to be 
assessed carefully in surgical patients.
Initial reports have indicated that these drugs may be used to 
relieve moderate to severe postoperative pain, and that they can be 
used to replace opioids. Such claims have to be substantiated 
because, although there have been clinical investigations using 
ketorolac, many have only been single-dose studies performed at 
different times after various types of surgical incisions, some of 
which would be less painful than others. Therefore, there is a need 
for a clinical investigation comparing ketorolac with conventional 
opioid therapy over a period of time after a standard surgical 
incision.
The non-steroidal anti-inflammatory analgesics do not have 
opioid-like effects, but they do unfortunately have adverse effects 
as a consequence of their mechanism of action, inhibition of tissue 
prostaglandin production. Such effects include (amongst others) 
impairment of platelet and renal function and peptic ulceration. It 
is not known whether such adverse effects will be seen when the drugs 
are given for a short time after surgery. Although some 
investigations have been performed in volunteers, there is an urgent 
need for careful assessment of these possible adverse effects of 
ketorolac and diclofenac in surgical patients, in whom any platelet 
and renal effects would be of prime importance.
In this thesis, the efficacy of ketorolac as a postoperative 
analgesic is further examined, and the potential adverse effects of 
these aspirin-like drugs investigated in surgical patients.
-23-
1.2 Aspirin
The analgesic, anti-inflammatory and anti-pyretic properties of 
an extract of willow bark was first described in the middle of the 
eighteenth century (1). The active ingredient was a glycoside, 
salicin, isolated in 1829 by Leroux. In 1875 sodium salicylate was 
introduced for the treatment of rheumatic and other fevers. Acetyl 
salicylate was synthesised by Hoffman and introduced into medical 
practice in 1899 by Dreser under the name 'aspirin', and quickly 
became accepted as an analgesic for the treatment of mild to moderate 
pain.
In the latter part of the nineteenth century more chemical 
compounds sharing some of the properties of the salicylates were 
synthesised. The most important of these were derivatives of para- 
aminophenol, and of these paracetamol is used today.
1.3 The non-steroidal anti-inflammatory analgesic drugs (NSAIDs)
In this century various synthetic substances have been developed 
with analgesic, anti-inflammatory and anti-pyretic properties like 
aspirin. One of the earliest was indomethacin, and now there are many 
compounds of different chemical structures in this group, known as 
the non-steroidal anti-inflammatory analgesic drugs or NSAIDs. These 
can be classed according to their basic chemical structure as 
pyrazolones, oxicams, and carboxylic acids:
-24-
The NSAIDs
Pyrazolones
Dipyrone
Oxicams
Piroxicam
Carboxylic acids
Salicylates: acetylsalicylic acid, diflunisal
Propionic acids: ibuprofen, naproxen, naproxen sodium, fenbufen, 
fenoprofen, ketoprofen.
Acetic acids:
Indolacetic acids: indomethacin 
Pyrrolacetic acids: ketorolac 
Phenylacetic acids: diclofenac
Anthranilic acids: mefenamic acid, floctafenine
As a group, the NSAIDs have anti-inflammatory, anti-pyretic, and 
analgesic actions like aspirin. Those offering the greatest potential 
for postoperative use have marked analgesic effects with a relatively 
mild anti-inflammatory action (2).
1.4 Prostaglandins
These substances were first described by Von Euler as locally 
active tissue agents which produce smooth muscle contraction. Their 
name results from the early discovery of their high rate of release
from the prostate (3).
Various types of prostaglandins have now been recognised, and are
all based on a 20-carbon chain molecule. The names given to
individual prostaglandins relate to the chemical methods originally 
used to isolate them. For example, prostaglandin E (PGE) was isolated 
in ether, and prostaglandin F (PGF) in phosphate (fosfate in 
Swedish). Prostaglandins are one family of the eicosanoids ('eicosa' 
indicating 20), oxygenated metabolites of arachidonic acid and other 
polyunsaturated fatty acids of about 20 carbons in length, including 
leukotrienes and other lipoxygenase products (4).
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1.4.1 Synthesis The basal rate of prostaglandin production is 
low, and synthesis is activated in response to various tissue stimuli 
or trauma when tissue phospholipases release arachidonic acid from 
membrane phospholipids (4,5). Prostaglandins are produced from 
arachidonic acid by the enzyme prostaglandin endoperoxide (PGH) 
synthase which is a membrane bound glycoprotein (molecular weight 
72,000 daltons) which has cyclo-oxygenase and hydroperoxidase 
catalytic activities (4,6). Initially the cyclo-oxygenase inserts two 
molecules of oxygen into arachidonate to yield the intermediate 
endoperoxide PGG2 , which is converted by the hydroperoxidase to PGH2 , 
from which prostaglandins and thromboxanes are produced. It has been 
demonstrated that one gene controls the production of prostaglandin 
endoperoxide synthase (6). This gene has been characterised and the 
structure of human cyclo-oxygenase deduced as being similar to the 
enzyme in various animals (7). The principal products of cyclo- 
oxygenase are the cyclic endoperoxides PGG2 and PGH2 , prostaglandins
D2 , F2a * I2 (prostacyclin), and thromboxane A 2 (4).
Arachidonic acid can also be metabolized by a different pathway 
involving the lipoxygenase enzyme, to produce various substances 
including leukotrienes and slow reacting substance (4). This 
metabolic pathway is not directly affected by cyclo-oxygenase 
inhibitors.
1.4.2 Catabolism Prostaglandins are broken down rapidly after 
being formed to inactive metabolites and are not thought to circulate 
in the bloodstream unchanged (8,4). There are specific enzymatic 
pathways for the catabolism of prostaglandins but, in addition, some 
cyclo-oxygenase products are chemically unstable. For example, 
prostacyclin (PGI2 ) spontaneously undergoes rapid nonenzymatic
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hydrolysis to 6-keto-PGFia which is then enzymatically metabolized to 
2,3-dinor 6-keto-PGFia . Similarly thromboxane A£ is very unstable, 
degrading quickly to thromboxane B2 (TXB2 ). The rapid spontaneous 
breakdown of these substances means that measurement of the inactive 
metabolite is often used as a reliable indicator of the rate of 
synthesis of the parent compound.
Enzymatic and nonenzymatic breakdown tend to limit the action of 
prostaglandins to the site of synthesis, and they can be thought of 
as local hormones allowing tissues to react to local conditions in 
response to specific stimuli without having systemic effects (5).
1.5 Mechanisms of action of aspirin and the NSAIDs
Many of the effects of these drugs, including analgesia; can be 
attributed mainly to inhibition of tissue prostaglandin synthesis. 
This may not explain all the actions of the NSAIDs, which may 
additionally be produced by the inherent ability of these chemical 
substances to interfere with the cellular processes involved in 
neutrophil activation by inflammatory stimuli.
1.5.1 Inhibition of prostaglandin synthesis (figure 1) Although 
salicylates had been used clinically since the nineteenth century it 
was not until the middle of the twentieth century that their 
mechanism of action was discovered. In 1971 aspirin and indomethacin 
were shown to inhibit the production of prostaglandins in various 
tissues (9,10,11).
It has now become clear that NSAIDs work by inhibiting the cyclo- 
oxygenase component of prostaglandin endoperoxide (PGH) synthase 
(12,13,1,6), and thus prevent the synthesis of prostaglandins from 
membrane phospholipids. The NSAIDs and aspirin are sometimes
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Figure 1 The mechanism of action of the NSAIDs.
therefore described as "cyclo-oxygenase inhibitors". Aspirin first 
binds with the cyclo-oxygenase site of PGH synthase and then 
acetylates the protein at Ser530, thereby interfering irreversibly 
with arachidonic acid interaction (6). Acetylation of PGH synthase at 
the serine group by aspirin leads to loss of the cyclo-oxygenase, but 
not hydroperoxidase, activity (14). Unlike aspirin, the NSAIDs do not 
acetylate cyclo-oxygenase, but inhibit it reversibly and therefore 
only affect prostaglandin synthesis while there are effective plasma 
levels of the drug present. By inhibiting cyclo-oxygenase, aspirin 
and the NSAIDs also prevent the production of thromboxanes.
Paracetamol, which has anti-pyretic and analgesic but not anti­
inflammatory effects, may primarily inhibit cyclo-oxygenase in the 
central nervous system, whereas the NSAIDs affect the enzyme in 
various tissues (15).
1.5.2 Other mechanisms of action Although the mechanism described 
above is accepted for the analgesic and antipyretic effect of aspirin 
and the NSAIDs, it has become obvious that it may not fully explain 
their anti-inflammatory effects (16). Certain problems have persisted 
in explaining the anti-inflammatory action of NSAIDs solely by an 
effect on prostaglandin synthesis. For example, sodium salicylate has 
no effect on prostaglandin synthesis but is an effective anti­
inflammatory agent, and aspirin itself exhibits anti-inflammatory 
effects only at doses far higher than those required to inhibit 
prostaglandin synthesis.
It seems that some of the anti-inflammatory action of these drugs 
may result additionally from a completely different mechanism; 
inhibition of neutrophil activation by inflammatory stimuli (16,17). 
When exposed to certain ligands, neutrophils are activated by 'twin
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signals', intracellular calcium and protein kinase C, and NSAIDs seem 
to affect these signals, inhibiting neutrophil aggregation in vivo 
and in vitro (18). This may be a chemical effect related to NSAID 
molecular structure, as they are planar lipophilic molecules which 
inhibit many membrane processes. NSAID inhibition of cell aggregation 
extends even to primitive marine cell cultures which do not 
synthesise prostaglandins (16,18), suggesting that these effects are 
a basic chemical property of the drugs.
1.5.3 The analgesic effect of NSAIDs Tissue injury leads firstly 
to nociception by damage to nerve endings, secondly to inflammation 
with the release of chemical substances, including prostaglandins, 
from damaged tissues, and thirdly to hyperalgesia produced by 
sprouting of damaged nerves and capillaries, and invasion of 
phagocytes and fibroblasts (19,20,21).
Prostaglandins are involved in the tissue reaction to injury, and 
PGI2 and PGE2 produced at the site of tissue damage sensitise pain 
receptors to histamine and bradykinin and produce hyperalgesia 
(12,19,22). It is unclear whether prostaglandins produce pain 
themselves or whether they only increase the effect of other painful 
stimuli on nerve endings. Nociceptors are known to be sensitised by 
painful stimuli and prostaglandins may have a role in this process 
(23). In addition, PGE increases the response from isolated single 
afferent C fibres in response to heat and bradykinin, an effect 
prevented by lysine salicylate (24). By preventing prostaglandin 
synthesis, NSAIDs inhibit nociceptor sensitisation and act as 
analgesics (12,22,5).
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Because they are thought to act by inhibiting cyclo-oxygenase in 
damaged tissues, NSAIDs have been described as peripherally acting 
analgesics. Although this is the case, paracetamol, which is not 
usually classed as an NSAID, differs in that it is thought to act by 
inhibition of cyclo-oxygenase in the central nervous system (15) 
without the peripheral side-effects of the aspirin-like drugs. It may 
be that different drugs inhibit cyclo-oxygenase and prostaglandin 
production in different tissues. The NSAIDs may also have a central 
effect in addition to their peripheral action, as aspirin has been 
shown to have effects on the central nervous system (25) and NSAIDs 
do diffuse into the cerebrospinal fluid (26). Indomethacin, 
ibuprofen, and diclofenac depress the evoked response of rat thalamic 
neurones to peripheral nerve stimulation in a dose-dependent fashion, 
and this central action may contribute to their analgesic effect 
(27).
1.6 Pain relief after surgery
Despite the widespread availability of powerful analgesics, 
patients can still experience severe pain for an appreciable time 
after surgery (28,29). This seems unacceptable when modern 
anaesthesia allows the painless performance of surgery. The 
importance of improving postoperative analgesia has been emphasised 
in the findings of a recent joint anaesthetic and surgical commission 
on this subject (30). Opioids are the mainstay of postoperative 
analgesia, with local anaesthetic techniques being used increasingly 
commonly. NSAIDs are now available in parenteral forms, and may be a 
useful addition to existing techniques for postoperative analgesia 
(31,19).
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1.6.1 Opioids At present, opioids are normally used to provide 
analgesia after operation, but, although they are powerful 
analgesics, they are often not employed effectively. Fear by the 
prescribers of overdosage and creating dependence seems to limit 
their administration (32,28). In addition, opioids are associated 
with harmful side-effects even at normal doses. Sedation, respiratory 
depression, disturbances of breathing patterns, nausea and vomiting 
are all associated with their use (33).
1.6.2 Local anaesthetic techniques Nerve blockade can give 
excellent postoperative pain relief, but circumstances may limit the 
application of local anaesthesia. Peripheral nerve blocks cannot be 
performed for all operations, and there is often a problem of 
providing analgesia when the effect wears off. Spinal analgesia can 
be used for many types of operation, and continued into the 
postoperative period to provide analgesia, but potential side-effects 
restricts the use of this technique to high-dependency areas.
1.6.3 NSAIDs There is therefore a need for alternative 
pharmacological agents to complement or replace existing methods for 
pain relief after operation. The NSAIDs may fulfill that role (31), 
and are mentioned in the report of the commission into postoperative 
pain as drugs worthy of further investigation, although their side- 
effects are noted (30). Potentially, they offer effective analgesia 
without the morphine-like side effects of respiratory, central 
nervous, or gastrointestinal depression, and they do not produce 
addiction.
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1.7 The NSAIDs as postoperative analgesics
To be useful after surgery, when the patient usually cannot take 
oral medications, a NSAID would have to be available as a parenteral 
preparation. Intravenous forms of salicylates are available, but not 
widely used. Indomethacin can be given intravenously and by 
suppository, but side-effects have limited its use. Diclofenac 
(Voltarol, Geigy Pharmaceuticals) is available as an injection for 
intramuscular use, as well as tablet and suppository preparations, 
and is increasingly being used to relieve pain after operation. 
Ketorolac trometamol (Toradol, Syntex Pharmaceticals Ltd) is a new 
drug which has been licensed recently for intramuscular use as an 
analgesic, but has not yet been marketed in the United Kingdom by the 
manufacturer.
1.7.1 Salicylates Aspirin is normally considered to be an oral 
analgesic for relief of mild or moderate pain, but intravenous 
preparations of salicylates have been compared with opioids in the 
presence of severe pain after surgery (34,35,36). Lysine acetyl 
salicylate (LAS) 1.8g intravenously is equivalent to lg of aspirin, 
and a single intravenous bolus gave poor relief of severe, immediate, 
postoperative pain compared with morphine 10 mg intramuscularly (36). 
Studies using continuous infusions of LAS have, however, produced 
more encouraging results. After inguinal herniorrhaphy, LAS infusions 
were as effective as morphine and associated with less drowsiness, 
nausea, and vomiting (34). Following thoracic surgery, LAS 7.2g over 
24 hours gave equivalent analgesia to morphine 40mg, but the authors 
did note that the salicylate was not as effective in the face of 
severe pain present in the immediate postoperative period (35). After 
major gynaecological surgery, LAS was at least as good an analgesic
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as morphine, and tended to produce less nausea, vomiting, and 
respiratory impairment (37). Although such studies give a favourable 
view of infusions of LAS, the drug is not used in practice, perhaps 
as a result of the high incidence of injection site problems 
including venous thrombosis.
1.7.2 Indomethacin Indomethacin has marked anti-inflammatory 
activity, and is normally used for the treatment of specific 
conditions as gout. A limited number of investigations have used 
indomethacin after surgery, but the lack of an intramuscular 
preparation has probably restricted the use of this drug.
An early study using indomethacin (lOOmg by suppository, 8 hourly 
for 3 days) found an impressive reduction in pain intensity and 
morphine requirement, and some evidence of improved respiratory 
function after major abdominal surgery (38). Although the analgesic 
effect was promising, the platelet side-effects were noted because 
indomethacin was associated with bleeding problems, including wound 
haematoma, haematemesis, and increased loss from surgical drains 
(38).
Efficacy has been confirmed in other clinical studies mostly 
using indomethacin by suppository. 0.8 mg/kg intravenously given 
before surgery, followed by 100 mg rectally 8 hourly, reduced opiate 
requirements and improved analgesia a little after hysterectomy, but 
again there was an associated increase in bleeding (39), a side- 
effect also confirmed in other studies (40). Given by suppository 
after thoracotomy, indomethacin (400mg, then 100 mg 12 hourly) 
improved analgesia and reduced opioid requirements, without side- 
effects (41). Indomethacin has been used in paediatric surgery, and 
in children after general surgical operations a bolus of intravenous
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indomethacin 0.35 mg/kg followed by 0.07 mg/kg/h improved analgesia 
and reduced the incidence of pyrexia with no serious adverse effects, 
although bleeding was increased a little (42).
1.7.3 Piroxicam Piroxicam (Feldene, Pfizer) is not available in a 
parenteral preparation, but oral administration after hip surgery 
performed under spinal anaesthesia reduced patient requirements for 
morphine by half, with no significant side-effects (43). Pretreatment 
with piroxicam before oral surgery reduced analgesic requirements and 
increased the time before analgesia was requested (44).
1.7.4 Diclofenac Diclofenac (Voltarol, Geigy Pharmaceuticals) is 
available as tablets and suppositories as well as a preparation for 
intramuscular use. The injection has been promoted for postoperative 
use in a dose of 75 mg intramuscularly twelve hourly. There have been 
a considerable number of studies concerning the postoperative use of 
diclofenac (45), although no direct comparison has been made with 
opioids after upper abdominal surgery.
Intramuscular diclofenac can be given in a dose of 75 mg up to 
twice daily, and because of the short half-life (45) injections can 
be repeated after only thirty minutes (Data sheet, Voltarol, Geigy 
Pharmaceuticals). Parenteral diclofenac should only be given for up 
to two days by deep intramuscular injection because of injection site 
problems, and the total daily dose should not exceed 150 mg (data 
sheet). These safety restrictions on diclofenac administration are 
often misinterpreted as meaning that intramuscular diclofenac is long 
acting and only has to be given every twelve hours. In fact, the 
elimination half-life of diclofenac is only one to two hours (45, 
data sheet, Voltarol) suggesting that any effect is short lived, and
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the safety restrictions on dosage should be recognised as a clear 
disadvantage. As with most NSAIDs, there is a lack of information 
concerning safety evaluation of this drug when used after surgery.
In a double blind, randomized, study performed the day after hip 
surgery, diclofenac 75 mg produced better analgesia than pethidine 50 
mg, with fewer side-effects (46). After hip replacement, diclofenac 
75 mg was a better analgesic than papaveretum 10, 15, and 20 mg (47). 
In the same study, the diclofenac patients also resumed walking more 
quickly, had less cognitive impairment, and were better in overall 
nursing scores of well being. This study can be criticised because it 
was not completely blinded. The analgesic regimens were different: 
the diclofenac group were given regular injections while the 
papaveretum patients only received injections on demand.
After major abdominal surgery, diclofenac 75 mg twelve hourly 
significantly reduced morphine requirements by 30% on average as 
delivered by a patient controlled analgesic device, although concern 
was expressed about the effect on platelets and bleeding (48). In 
contrast, other studies have found that single doses of diclofenac 
confer no advantage after upper abdominal surgery. Rectal diclofenac 
did not augment opioid analgesia after upper abdominal surgery (49), 
and intravenous diclofenac showed no analgesic effect in the 
immediate postoperative period (50).
Diclofenac is an effective analgesic after minor surgery. After 
day-stay arthroscopy surgery, diclofenac given at induction of 
anaesthesia was as effective as fentanyl (51). Pretreatment with 
diclofenac markedly reduces pain after removal of impacted wisdom 
teeth, intravenous administration giving better analgesia than 
fentanyl (52).
-35-
Various studies have found that diclofenac is useful in 
paediatric surgery. In children having tonsillectomy, rectal 
diclofenac is as effective as pethidine (53) and papaveretum (54). 
After inguinal herniotomy in children, rectal diclofenac was as 
effective as caudal local anaesthetic block with bupivacaine (55).
1.7.5 Ketorolac Ketorolac trometamol (Toradol, Syntex 
Pharmaceuticals Ltd) (56) is a new drug which is being assessed as a 
postoperative analgesic (2), and will be available for general use in 
the near future. Ketorolac is available already in the United States 
for short-term management of pain, and it is the first injectable 
NSAID to be marketed as an analgesic in that country (57).
Chemically it is a pyrroloacetic acid and is similar to tolmetin 
and zomepirac. It is prepared as the trometamol salt to increase 
solubility (the US terminology is tromethamine). The intramuscular 
preparation is a 3% solution in water with ethanol.
In animal models, ketorolac has analgesic, antipyretic, and anti­
inflammatory actions attributed to prevention of prostaglandin 
synthesis by inhibition of the enzyme cyclo-oxygenase, and at 
clinically used doses it has a much greater analgesic than anti­
inflammatory effect (58). In animal experiments, the systemic 
analgesic effect of ketorolac was some 800 times more than aspirin, 
and was greater than the systemic anti-inflammatory action (58,59).
Ketorolac does not have the side-effects associated with opioids. 
It does not produce respiratory depression (60,61), reduction of 
gastrointestinal motility (62), addiction (63), or psychomotor 
effects (64).
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The absorption of ketorolac is rapid after oral ingestion or 
injection. After oral administration, the average time to peak plasma 
concentration is 48 minutes, and, after intramuscular injection, 54 
minutes (65,66). The bioavailability of oral ketorolac is very high, 
with little presystemic metabolism, and like other NSAIDs it is 
extensively, 99%, protein bound (67,57). The volume of distribution 
at steady state is 0.1 litre kg~l (65,66). In pregnancy, ketorolac 
crosses the placenta, but transfer is low in comparison with the 
opioids (68). Elimination is mainly by glucuronic conjugation and 
urinary excretion, although parahydroxylation also occurs (66). The 
elimination half-life of ketorolac is around four to six hours 
(66,67) but this may be prolonged in the elderly (69) or by renal 
impairment (70), necessitating a reduction in dose.
As well as oral and parenteral systemic injections, ketorolac has 
been studied as a local gel for ankle sprains (71), and an opthalmic 
preparation for inflammatory eye disorders (72,73).
Oral ketorolac has been investigated as an analgesic after 
various forms of surgery. 10 mg ketorolac was as effective as 650 mg 
of aspirin in relieving postpartum uterine pain (74). After 
gynaecological surgery, ketorolac 10 mg was as effective as 
paracetamol lOOOmg and codeine 60 mg (75). A  number of studies have 
used ketorolac after orthopaedic surgery when opioids are no longer 
required and have found that ketorolac is as effective as 
paracetamol, diflunisal,and dihydrocodeine (76,77,78).
Intramuscular ketorolac has been shown to be an effective 
analgesic after minor surgery. Ketorolac 30 and 90 mg was more 
effective than pethidine 50 or 100 mg after oral surgery (79), and 30 
mg was superior to pentazocine 30 mg in treating postoperative pain 
(80). When given as an intramuscular premedication before minor
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surgery, ketorolac was as effective as morphine in reducing 
postoperative pain, effective blood levels were attained, but the 
opioid gave more sedation (81).
Ketorolac given by injection has also been found to be equipotent 
with opioids after major surgery. In single dose intramuscular 
studies performed on the first or second day after operation, 
ketorolac 10, 30 and 90 mg were compared with morphine 6 and 12 mg 
after major surgery. In the presence of moderate to severe 
postoperative pain, ketorolac 30 or 90 mg was as effective as 
morphine 12mg with a longer duration of action. Ketorolac 30 or 90 mg 
was a better analgesic than morphine 6 mg, and ketorolac 10 mg was as 
effective as morphine 6 mg (82,83).
The effect of combining ketorolac and opioid therapy has been 
studied after upper abdominal surgery. Continuous intramuscular 
infusions of ketorolac (1.5 and 3 mg/hr) reduced patient opioid 
(morphine) requirements by 30% over twenty-four hours. The ketorolac 
group had lower pain scores and those patients given the higher dose 
of ketorolac had lower postoperative increases in PaC02 than the 
control group (84). Ketorolac administration may therefore have a 
morphine sparing effect which also minimises the respiratory side- 
effects of the opioid.
1.7.6 Other NSAIDs Ibuprofen, given by suppository, significantly 
reduced patient opioid requirements after lower abdominal surgery 
(85). Intravenous ketoprofen was associated with better recovery, 
lower pain scores, and a reduced requirement for further analgesia 
than pethidine following nasal surgery (86).
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1.8 NSAID side-effects
Unfortunately, the NSAIDs do have side-effects as a consequence 
of their mechanism of action, and they are a major cause of serious 
adverse drug reactions reported to the regulatory authorities 
(87,88). Because prostaglandins act as local tissue regulators, 
inhibition of their synthesis and release may produce unfortunate 
adverse effects (5). Essentially these effects are well known and 
recognised as a consequence of long term aspirin or NSAID therapy 
(89,87). In surgical patients, the main concerns are the platelet, 
renal, and peptic ulceration side-effects (30). As yet few studies 
have investigated the side-effects produced when NSAIDS are given for 
a short period after surgery, and most reports and investigations of 
toxicity concern long term administration. In certain respects the 
surgical patient may be more at risk from NSAID induced side-effects 
and this led one reviewer to comment:-
" NSAID therapy should also be withheld from patients who are 
about to undergo surgery because of the risk of acute renal 
failure, as well as of impaired hemostasis due to the effects of 
these agents on platelet function" (90).
There have been many studies on the analgesic effect of NSAIDs 
after surgery, but there is a definite paucity of information about 
the safety aspects of these agents, especially with regard to the 
platelet and renal effects.
1.8.1 Platelet function and haemostasis Platelet cyclo-oxygenase 
is essential for the production of cyclic endoperoxides and 
thromboxane A 2 , important mediators of aggregation and
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vasoconstriction, processes which constitute the primary haemostatic 
response to vessel injury (91). Glycoprotein receptors for TxA£ and 
cyclic endoperoxides have been isolated in the membranes of human 
platelets using radiolabelled ligands (92,93). While it is clear that 
NSAIDs and aspirin, which has a similar inhibitory effect on cyclo- 
oxygenase, inhibit aggregation and prolong bleeding time in 
volunteers (94,95,96), there is little information on the 
perioperative situation where the haemostatic response may be altered 
by the stress of surgery.
Aspirin ingestion is well recognised as a factor in increasing 
blood loss after surgery (97), a problem also encountered with NSAIDs 
(38,39,48). Aspirin ingestion in the seven days before cardiac 
surgery increases the risk of reoperation for rebleeding, the 
requirement for blood products including platelets and prolongs the 
patients stay in intensive care and in hospital (98). The haemostatic 
problem after aspirin may last up to 14 days because it inhibits 
platelet cyclo-oxygenase irreversibly by acetylation (99,6,14). 
Haemostasis returns to normal after aspirin only when new platelets 
have been synthesised because, once formed, they are incapable of 
making new enzymes. In comparison, other NSAIDs are reversible cyclo- 
oxygenase inhibitors and only affect platelets while there are 
effective circulating concentrations of the drug present 
(99,100,101). It is likely therefore, that the duration of the anti­
platelet effect of NSAIDs will be shorter than aspirin, although the 
magnitude of effect may be the same.
Ketorolac is known to inhibit platelet function in volunteers 
(102,103), as does diclofenac (45), which has produced severe 
spontaneous bruising in a patient (104). There is little information
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about the importance of the anti-platelet effects of these drugs in 
surgical patients, although concern has been expressed about using 
diclofenac when extensive surgical dissection is required (48).
Surgical patients also receive other agents which can affect 
bleeding and could interact with a NSAID to produce increased 
operative loss. Postoperative pulmonary embolus is an important cause 
of death for which heparin, dextran, and warfarin may be used as 
prophylaxis (105,106). The problem is that these agents could 
interact with NSAIDs and lead to increased bleeding at operation.
The combination of heparin and ketorolac has been studied in 
volunteers (103) and suggests that any interaction is probably 
clinically insignificant. Few studies have examined the effect on 
haemostasis and operative blood loss of giving a NSAID and 
subcutaneous heparin together to patients having surgery.
Dextran is also used during surgery in certain circumstances as 
prophylaxis against venous thrombosis, especially after major 
orthopaedic procedures (105). There has been no investigation of the 
combined effect on haemostasis of giving dextran and a NSAID 
simultaneously.,The consequences of any interaction between NSAIDs 
and dextran may be severe during surgery and should be investigated 
before the combination is given to patients.
Surgical patients may be on long term warfarin therapy, but this 
is usually discontinued for the time of surgery. Warfarin may be 
useful in low doses as prophylaxis against pulmonary emboli (105), 
although this is not common practice. Volunteer studies have shown 
that simultaneous administration of ketorolac with warfarin produced 
no interaction, although close monitoring of patients on such 
combination therapy was advised (107).
-41-
1.8.2 Renal function The adverse renal effects of NSAIDs are 
serious and have been well described, representing a significant 
problem in the use of these drugs (90,108,109,110,111,112). Host 
studies have concerned the effect of long term oral NSAID intake for 
medical conditions, and have found that regular consumption of non­
narcotic analgesics should be routinely considered as a risk factor 
for any non-congenital cause of chronic renal failure (113). As yet, 
little work has been done on the acute effects on renal function of 
short term parenteral administration of NSAIDs in the perioperative 
period (19).
Renal prostaglandin physiology The kidney has enzymes for the 
metabolism and catabolism of most prostaglandins (114) where they 
seem to act as local tissue hormones (115). Renal prostaglandins have 
various physiological roles, including the maintenance of blood flow 
and glomerular filtration rate (GFR) in the presence of 
vasoconstrictor hormones, regulation of tubular handling of 
electrolytes, and modulation of the effects of other renal hormones 
(116,90,108,115).
Prostacyclin (PGI2 ) and PGE2 are the prostaglandins produced in 
greatest abundance in the kidney. There is a degree of specialisation 
of function and these two prostaglandins are produced in different 
sites and have different actions (117,112,114). PGI2 is produced 
mainly in the cortex in renal vessels and glomeruli, and acts as a 
vasodilator and maintains GFR. PGE2 is a medullary hormone 
synthesised in the collecting tubules where it enhances sodium, 
chloride and water excretion, in the medullary interstitial cells 
producing vasodilatation and natriuresis, and in the glomeruli 
maintaining glomerular filtration rate.
-42-
Other prostaglandins are produced in the kidney, including PGF2a 
which increases NaCl and water excretion in the collecting tubules, 
and thromboxane (TXA2 ), which may reduce GFR after renal 
transplantation (118).
Prevention of renal prostaglandin synthesis by NSAIDs can 
interrupt these physiological processes and lead to clinically 
significant adverse effects in certain circumstances, even after only 
a few doses (90,108,109).
Renal blood flow Prostaglandins E2 D2 and I2 (prostacyclin) are 
potent renal vasodilators which have a protective role during acute 
renal hypoperfusion (119). Normally, renal prostaglandins are thought 
to have little effect on the regulation of blood flow, but in certain 
clinical states their importance is increased greatly.
Renal vasoconstrictor hormones such as renin, angiotensin, 
noradrenaline, and vasopressin produce a compensatory increase in 
renal vasodilator prostaglandins by induction of the enzyme 
phospholipase (115). This enzyme breaks down membrane phospholipids 
to produce arachidonic acid, the basic metabolic requirement for 
prostaglandin synthesis by cyclo-oxygenases (figure 1). The resultant 
increase in prostaglandin production tends to maintain renal 
perfusion, counteracting the effect of the vasoconstrictor hormones.
In clinical conditions where there are high concentrations of 
circulating vasoconstrictors, blood flow to the kidney may become 
dependent on renal prostaglandin synthesis. NSAID administration can 
then lead to impaired renal function and failure by removing the 
protective vasodilator effect of prostaglandins and allowing the 
unopposed action of circulating vasoconstrictor hormones
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(90,108,109,110,115,120). Medical conditions characteristic of this 
include cardiac failure, cirrhosis with ascites, and hypovolaemia and 
hypotension.
During and after anaesthesia and surgery there is an increase in 
the level of hormones including catecholamines, angiotensin, 
vasopressin, and renin described as part of the metabolic response to 
stress (121,122). Such hormonal changes can impair renal function 
during anaesthesia (123,124,125). In the face of such increased 
vasoconstrictor hormonal activity, it has been postulated that there 
is a compensatory increase in the production of local renal 
prostaglandin vasodilators and that the anaesthetised patient is 
particularly susceptible to the adverse renal effects of NSAIDs 
(90,120,109). It is indeed known that the anaesthetised, 
laparotomised, dog is much more sensitive to the adverse renal 
effects of indomethacin than the awake animal (126).
The risk of unexpected sudden blood loss occurring leading to 
acute hypotension during surgery may further increase the risks 
associated with NSAID administration. During experimental haemorrhage 
and hypotension, renal prostaglandins oppose the vasoconstrictor 
action of angiotensin II and maintain blood flow (127). During 
hypotension renal prostaglandins activate specific R2 chemoreceptors 
which excite afferent nerves and thus contribute to autoregulation of 
renal blood flow (128). Administration of NSAIDs could also impair 
this protective mechanism of prostaglandins during episodes of 
hypotension, which can occur unexpectedly during surgery.
Renal tubular function Prostaglandins are also important in 
determining the renal tubular handling of electrolytes (115,90). 
Prostaglandins are thought to inhibit reuptake of chloride ions from 
the ascending limb of the loop of henle, resulting in increased
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excretion of salt and water. Animal experiments have shown that 
normal tubular excretion of sodium and water is dependent on 
prostaglandins which act by suppression of renal medullary sodium- 
potassium-ATPase (129). PGE^ stimulates chloride ion secretion in 
renal epithelial cells (130). Infusions of iloprost, a synthetic 
prostacyclin analogue, reduces the reabsorption of sodium in the loop 
of Henle in humans, increasing salt and water excretion (131).
Interaction with renin and vasopressin Renal prostaglandins 
increase renin release and inhibit the effect of vasopressin on the 
collecting ducts (115,116,108).
Prostacyclin infusions increase renin release in man (132). 
Because renin is one the main factors in controlling aldosterone, 
renal prostaglandins can increase aldosterone release and potassium 
excretion. Excessive renal prostaglandin production has been 
implicated in the hypokalaemic alkalosis associated with the high 
renin, aldosterone, and angiotensin II concentrations of Bartter's 
Syndrome in which platelet defects are also present (133).
NSAIDs are known to potentiate vasopressin (108,115,116). There 
is an interaction between vasopressin and renal prostaglandins so 
that each modulate the effect of the other (134). Vasopressin 
increases the production of cyclic AMP by renal tubular cells thus 
increasing permeability and water reabsorption. This effect is 
opposed by renal prostaglandins, and it has been demonstrated that 
PGE2 blocks the effect of vasopressin hormone on the collecting 
tubule increasing water excretion (108,134). Indeed, indomethacin has 
been used to treat nephrogenic diabetes insipidus (135).
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NSAIDs and renal function In physiological terms, renal 
prostaglandins are therefore important in the control of renal blood 
flow, renal tubular function, renin and aldosterone release, and the 
action of vasopressin. By inhibiting prostaglandin production, NSAIDs 
may reduce renal blood flow and impair excretion of water and 
electrolytes (90,108,115,120). The clinical significance of this will 
depend on the patients general condition before the drug is 
administered (111).
There have been few studies on the renal effect of short term 
NSAID administration, but adverse effects can occur after only a few 
oral doses in susceptible individuals. In patients with asymptomatic 
renal failure a brief course of ibuprofen can precipitate acute renal 
failure (110). In susceptible patients, short acting NSAIDs may 
affect renal function even after a very short exposure (109,110).
Risk factors for NSAID nephrotoxicity include age (greater than sixty 
years), atherosclerosis, diuretic therapy, existing renal impairment, 
and states of renal hypoperfusion including cardiac failure, hepatic 
cirrhosis, and hypovolaemia (111). Many of these risk factors are 
present in patients having surgery, and general anaesthesia and 
surgery may produce an additional tendency towards NSAID 
nephrotoxicity. Therefore, many surgical patients may be susceptible 
to the adverse renal effects of NSAIDs, and clinical studies are 
required to investigate this.
Chronic renal failure A common cause of drug induced chronic 
renal failure is "analgesic nephropathy" involving interstitial 
nephritis and papillary necrosis. This is most often associated with 
phenacetin, but has been reported after other NSAIDs (90).
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Renal flank pain syndrome A sudden onset renal failure with 
haematuria and flank pain has been reported with various NSAIDs 
(136), and has occurred in a healthy volunteer after short term 
ketorolac therapy (data on file, Syntex Laboratories).
Before the routine use of NSAIDs in surgical patients can be 
recommended, detailed investigation of the renal effects is required.
1.8.3 Gastrointestinal effects The association of NSAIDs with 
gastric and duodenal ulcers is well recognised, but it is now 
becoming apparent that the large and small intestines are also 
affected.
Peptic ulcers Aspirin has been known to damage the human gastric 
mucosa for a considerable time (137), and many investigations have 
suggested that NSAIDs have a similar effect. The role of NSAIDs in 
peptic ulceration was recently reviewed, and the conclusion made 
that
"Non-steroidal anti-inflammatory drugs cause gastric ulcers and 
probably duodenal ulcers. The size of this risk is not clear, but 
the increased chance of involuntary presentation with 
haematemesis and melaena or perforation probably lies between a 
50% and a fivefold increase." (138)
The gastric and duodenal epithelia have various protective 
mechanisms against acid attack. These include the mucus layer, 
bicarbonate secretion, mucosal hydrophobic properties, rapid cellular 
regeneration after damage, and an abundant blood supply (139). Many 
of these factors involve prostaglandins and can be adversely affected 
by aspirin and NSAIDs (140,141), although the relationship between
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ulceration and these drugs continues to be questioned (142). The 
anti-platelet effect of NSAIDs may increase the risk of bleeding from 
ulcers, and the risk of upper gastrointestinal haemorrhage is 
significantly increased by these drugs (143). Gastric microvascular 
endothelium is a major target for aspirin injury, and damage and deep 
necrosis can be significantly reduced by arachidonic acid 
pretreatment (144). Such work indicates that prostaglandin production 
may be important at various and multiple sites in maintaining mucosal 
integrity. Attempts have been made to prevent NSAID induced ulcers 
using prostaglandin analogues and H2 receptor anatagonists. 
Misoprostol, a PGEi analogue, specifically reduces NSAID related 
gastric ulceration (145), but in contrast ranitidine prevents 
duodenal ulceration (146). NSAIDs have been shown to inhibit 
regenerative cell proliferation at the edge of ulcers, a critical 
mechanism for mucosal repair, and misoprostol reduces this harmful 
effect (147).
The clinical implication of this is unclear, as it is not known 
whether such effects will be produced by administering parenteral 
NSAIDs for a few days after surgery. Indeed, it could be that 
surgical patients are at increased risk of mucosal damage from 
NSAIDs, as they may be fasted for a period of days with deranged 
gastro-intestinal function, because of surgical manipulation and 
opioid administration, in addition to being stressed. Near-fatal 
peptic ulceration and bleeding can occur in post-partum patients with 
no previous history of problems after relatively short oral 
administration of NSAIDs, even after only ten days treatment (148). 
NSAIDs should be avoided after surgery if the patient has a history 
of peptic ulceration as this increases the chance of problems 
developing (146).
Little is known of parenteral diclofenac and ketorolac in this 
respect. Early animal experimentation suggested ketorolac had a 
favourable therapeutic ratio for gastrointestinal erosion (58), but 
studies in humans have been less reassuring. In a controlled 
endoscopic study, invasive gastric antral ulceration was present in 
four of five volunteers who had been given ketorolac 90 mg 
intramuscularly four times daily for five days, with evidence of a 
dose related effect (149). In the same study, the clinically 
recommended intramuscular dose (56,67) of 10 to 30 mg four times 
daily was found to produce some mucosal injury, but this was less 
than oral aspirin 650 mg four times daily (149). Oral ketorolac 
produces mild gastrointestinal symptoms in some patients within a few 
days, although no more than other NSAIDs (67,77).
Enteropathy NSAIDs can also have adverse effects on the lower 
gut, producing an enteropathy (150). It has been estimated that 10% 
of cases of newly diagnosed colitis may be related to NSAID ingestion 
(151). Animal work has shown that single large doses of indomethacin 
given to rats produce intestinal as well as gastric lesions and that 
these changes are temporally related to inhibition of prostacyclin 
synthesis (152). NSAID induced enteropathy in rats is associated with 
an increase in bowel permeabilty and resembles inflammatory bowel 
disease (153). The production of protective intestinal mucin is 
reduced by aspirin and increased by prostaglandins (154). Patients 
receiving long term NSAID therapy for arthritis have an abnormal 
increase in bowel permeability, affecting both the large and small 
intestine (155,156). NSAID therapy is associated with an enteropathy 
similar to that of Crohn's disease, and that this may persist for up 
to 16 months after ingestion (157). It is thought that by decreasing 
mucosal prostaglandin synthesis NSAIDs may impair bowel wall
integrity and allow bacterial invasion and damage. Recent 
enteroscopic studies have shown that small bowel ulceration is also 
associated with NSAIDs (158).
1.8.4 Aspirin sensitive asthma This is common in patients who 
have asthma and chronic rhinitis or nasal polyps (159). Bronchospasm 
occurs soon after aspirin ingestion, and patients can also be 
sensitive to other NSAIDs (160). The incidence is around 10% of 
asthmatics (estimates being from 3 to 20%), usually in middle age 
(159).
The mechanism is unclear, but the cyclo-oxygenase inhibitory 
activity of a drug is important (160). Cyclo-oxygenase inhibitors may 
divert more arachidonic acid to lipoxygenase metabolic pathways, 
producing substances which can precipitate bronchospasm, including 
leukotrienes and slow reacting substance (159). There may be an 
interaction here with the peptide endothelin-1 which may be involved 
in the exaggerated bronchial muscle tone in asthmatics (161), and 
which increases lipoxygenase products of arachidonic acid metabolism 
(162). Other factors could be involved as patients with this disorder 
have an abnormal in vitro response to aspirin of platelets, releasing 
cytotoxic mediators, a mechanism dependent on inhibition of 
prostaglandin synthesis and prevented by inhalation of nedocromil 
sodium, a new drug which stabilizes mast cells (163). The importance 
of this syndrome has been emphasised by reports of fatal bronchospasm 
in asthmatic patients after NSAID ingestion (164). Interestingly 
NSAIDs do not produce problems when given to patients with bronchial 
hyperresponsiveness from cigarette smoking (165). The ability of a 
NSAID to produce this syndrome is directly related to potency as a
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prostaglandin synthesis inhibitor (160). Ketorolac and diclofenac are 
very powerful inhibitors of cyclo-oxygenase, and it may be prudent to 
avoid them in all asthmatic patients.
1.8.5 Hepatotoxicity Aspirin and NSAIDs have hepatotoxic effects, 
normally after prolonged, excessive, exposure (166,167). Diclofenac 
has been associated with fatal hepatitis (168) which can develop 
within a few weeks of commencing therapy (169). Again the risk of 
precipitating hepatotoxicity as a consequence of a short course of 
NSAIDs is not known, although borderline increases in serum 
aminotransferase concentrations may occur in 15% of patients (57).
1.8.6 Injection site damage Intramuscular diclofenac can produce 
appreciable pain on injection, and is associated with muscle damage 
and increases in serum creatinine phosphokinase (CPK) (64). 
Preliminary studies have shown that intramuscular ketorolac does not 
produce muscle pain or rises in serum CPK (64,59), but further 
studies are required in patients receiving multiple injections. The 
irritant nature of the injectable preparation of diclofenac is 
emphasised by the observation that, when given intravenously, 
diclofenac results in venous thrombosis (170), although this may be 
reduced by diluting the drug in volumes of dextrose solution for 
infusion (52). Injection site pain is a significant problem with 
diclofenac, and has led to the widespread use of alternative routes 
of administration, including suppository.
1.8.7 Other side-effects Mild adverse nervous system effects have 
been reported after ketorolac, including somnolence, headache, and 
dizziness (57,67). Blood dyscrasias, erythema multiforme,
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anaphylaxis, urticaria, erythema multiforme, and pancreatitis have 
all been reported to be associated with NSAIDs, although they are 
uncommon (89,171).
In very preterm infants, indomethacin reduces cerebral blood flow 
and oxygen delivery, and could increase the risk of hypoxic brain 
injury (172). It is not known whether NSAIDs have this effect in 
older children or adults.
Some myocardial protection against coronary vessel occlusion can 
be conferred in animals by preconditioning episodes of ischaemia, an 
effect blocked by cyclo-oxygenase inhibitors, suggesting a protective 
role for prostaglandins, probably prostacyclin (173). It is unclear 
whether NSAIDs can increase the consequences of acute myocardial 
ischaemia in humans.
1.9 Aims of studies comprising the thesis
The aims of this thesis were to assess the efficacy of the new 
NSAID, ketorolac, and to evaluate the safety of ketorolac and 
diclofenac when given after surgery. Any potential respiratory 
benefits of using NSAIDs after surgery were examined. The acute 
effects of ketorolac and diclofenac on platelet function and 
haemostasis were investigated. Changes in renal function associated 
with ketorolac and diclofenac were observed.
1.9.1 Ketorolac as a postoperative analgesic 
Cholecystectomy study Ketorolac, 30 mg by intramuscular 
injection, was compared with morphine 10 mg. Initially a single dose 
pilot study was performed, and then a large study was completed of
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the effects of the drug over two days after upper abdominal surgery. 
The analgesic effect of ketorolac was compared with morphine and any 
side-effects noted.
Thoracotomy study In this study, ketorolac, 10 or 30 mg, with a 
placebo group, was given by regular intramuscular injection for two 
days to patients after thoracotomy, who also had free access to 
intravenous morphine by patient controlled analgesia (PCA, Abbott PCA 
plus infuser). Previous work had indicated that, when given in this 
manner, ketorolac had a clinically significant morphine-sparing 
effect (84,85) after abdominal surgery. Such an effect, if confirmed, 
would be very desirable after thoracotomy when the analgesic effect 
of opioids is often associated with depression of respiration and 
inhibition of expectoration. Analgesia and morphine usage was 
assessed, and arterial blood sampling performed to detect any 
respiratory benefits of ketorolac administration.
1.9.2 Platelet function
Ketorolac In the cholecystectomy study described above, platelet 
function was measured in a group of twenty patients. Platelet 
function was investigated in vivo (skin bleeding time) and in vitro 
(platelet aggregation in whole blood), and changes from control 
values observed after ketorolac or morphine. Surgical blood loss was 
also noted for all one hundred patients in the cholecystectomy study, 
and so the effect of ketorolac on platelet function and surgical 
blood loss was investigated. The effect of ketorolac on surgical 
blood loss was also examined in the thoracotomy study.
Ketorolac and dextran In a volunteer study, the haemostatic 
consequences of giving intramuscular ketorolac with intravenous 
dextran was investigated. Platelet function was assessed as before,
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and any interaction between ketorolac and dextran examined. Venous 
blood thromboxane, coagulation factors, and fibrinolysis were also 
measured. The incidence of injection site pain after ketorolac was 
also noted.
Diclofenac The effect of diclofenac on platelet function was 
investigated, in a similar fashion to ketorolac, in a group of twenty 
patients having thoracotomy.
1.9.3 Renal function
Ketorolac In the cholecystectomy and thoracotomy studies, plasma 
urea, creatinine, and electrolyte concentrations were measured before 
and after the investigation. Any changes were examined and compared 
with the control groups.
Unfortunately it was not possible to make further studies of the 
renal effect of ketorolac because the manufacturers (Syntex) were 
unwilling to release supplies of this unlicensed drug for such an 
investigation.
Diclofenac The effect of diclofenac 75 mg b.d. on renal function 
and renal prostacyclin generation was examined in patients having 
oesophagogastrectomy, and compared with a control group receiving 
morphine analgesia. Plasma creatinine and electrolytes, creatinine 
and free water clearances, and urinary sodium and potassium excretion 
rates were measured before and for two days after surgery. 
Perioperative renal prostacyclin generation was examined by measuring 
the production of the stable urinary metabolite, 6-keto-PGFia , on 
each study day. Changes in prostacyclin production and renal function 
were then examined for any effect of diclofenac.
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1.9*4 Other adverse effects Many of the recognised side-effects 
of NSAIDs have been described after chronic administration. In this 
thesis, the incidence of gastrointestinal, respiratory, and hepatic 
side-effects was observed after short-term drug administration of 
ketorolac in the postoperative period. All other adverse events, 
including pain on injection, were recorded.
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CHAPTER 2 
METHODS USED IN THIS THESIS
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2.1 Introduction
In this thesis, the efficacy and safety of using ketorolac and 
diclofenac after surgery is assessed. The efficacy of ketorolac was 
assessed by measurements of pain intensity and pain relief, and 
safety by the platelet and renal effects of the two NSAIDs and by the 
incidence and severity of any other adverse effects.
2.2 The assessment of pain and analgesia after surgery
A  considerable part of this thesis concerns appraisal of 
ketorolac as an analgesic and involves measurement of pain after 
surgery. Pain is difficult to assess and quantify at any time 
(174,175,176), but the postoperative period presents distinct 
problems (177,178,179,180).
Pain has been defined by the International Association for the 
Study of Pain as:
"an unpleasant sensory and emotional experience with actual or
potential tissue damage or described in terms of such damage"
(181).
Postoperative pain is related to the tissue damage of the 
surgical incision, and should diminish as wound healing occurs. It is 
therefore an acute pain which can be further defined as being:
"associated with a specific injury and which would be expected to
resolve with the healing of that injury" (182).
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The degree of pain observed after an operation will therefore 
depend not only on the patient's own sensory and emotional response 
to injury, but additionally on the incision performed and the time 
elapsed since surgery. The assessment of an analgesic in the 
postoperative period must therefore take account of these factors.
Patients may also be less able to comply with pain assessments in 
the immediate postoperative period because of the residual sedative 
effects of anaesthesia. This produces a tendency for analgesic 
studies to be performed later in the postoperative period when pain 
may have diminished significantly and patients can cooperate. The 
disadvantage of this is that analgesics found to be effective by such 
studies may nevertheless be unsuitable for use immediately after 
operation when pain intensity is greater and the quality of pain may 
be different. Ideally, methods of pain and analgesia assessment 
should be used which can be applied at any time after surgery.
2.2.1 Methodology of studies Postoperative pain studies should be 
designed to minimize the effect of the factors described above.
Surgery Pain intensity and duration will depend on the surgery 
performed, and investigations should ideally use a standard 
operation. The choice of operation is important as analgesic studies 
tend to more discriminating and productive when performed after major 
surgery, than after less painful procedures (177,178). The 
anaesthetic technique should also be standardized as this can affect 
postoperative pain and analgesic requirements. Subject and observer 
bias and other confounding variables should be minimized by ensuring 
that the study is double-blind and that treatment is allocated 
randomly (183). In particular, study groups should be balanced for 
age and sex as these affect analgesic requirements (184).
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Time of assessment Postoperative pain is transient and will vary 
depending when observations are made. Assessments should therefore be 
made at set times after surgery, preferably beginning soon after 
emergence from anaesthesia.
2.2.2 The subjective assessment of pain
Patient or observer The patient's own impression is the most 
important, but at times this may not be available, especially 
immediately after operation, and the assessment of an experienced 
observer may then provide valuable information. Ideally, one trained 
observer should assess all the patients in a study to reduce the 
variability of results.
Verbal rating scales (VRS) Both the patient and the observer can 
complete these for pain intensity. Commonly four point scores are 
used:
0 = no pain
1 = mild pain
2 = moderate pain
3 = severe pain
An alternative, simpler, score has been suggested for use by 
observers immediately after surgery when patients find it difficult 
to complete any scores (185):
0 = no pain
1 = pain which is not bad enough to need medication
2 = pain which needs relief
The advantage of these verbal rating scales is that they are 
easily performed, but their disadvantage is a relative lack of 
sensitivity.
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Numerical rating scales Pain is scored numerically, for example 
from 0 to 100. This may represent a compromise between simple verbal 
rating scales and visual analogue scales which patients sometimes 
find confusing.
Visual analogue scales (VAS) These are horizontal 10 cm lines 
marked 'no pain' (at 0cm) and 'worst possible pain' (at 10 cm). The 
line should be a least 10 cm to reduce variability (186). Patients 
mark the line at the point they feel is appropriate, and the distance 
from zero, in millimetres, gives a non-verbal measurement of pain.
VAS may be more discriminating than a VRS (187,188), although both 
may be reliable in the postoperative period and produce equivalent 
results (174).
Compared with simple rating scales more patient compliance is 
required for VAS, often preventing their use immediately after 
surgery. Some patients find it difficult to relate their pain to a 
horizontal line on paper at any time. Variations of the VAS have been 
used to overcome these problems including a pain slide rule which is 
marked 'no pain' and 'worst pain imaginable' at either end, and the 
score can be read directly from the back (189).
The McGill Pain Questionnaire (MPQ) This represents a more 
detailed, 'multidimensional' approach to pain assessment than the 
simple VRS and VAS rating scales (190). The MPQ consists of a number 
of adjectives from which the patient chooses those most appropriate 
to their pain state. It is designed to reflect three dimensions of 
pain; sensory, affective, and evaluative. Sensory word descriptions 
relate to the temporal, spatial, pressure, and thermal properties of 
pain. Affective words refer to tension, fear, and autonomic 
functions. Pain intensity is reflected by evaluative word 
descriptions. This multidimensional approach to pain has proven to be
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successful, although it is of limited use after surgery when patients 
may be unable to complete such a complicated test which takes 10 to 
20 minutes to do.
2.2.3 The objective assessment of pain
Modification of the stress response to surgery After surgery 
there are rises in blood pituitary adrenal, renal and sympathetic 
hormones, and metabolic factors including (122):
Pituitary - ACTH, B-endorphin, prolactin, growth hormone.
Adrenal/renal/sympathetic - cortisol, aldosterone, adrenaline,
renin, noradrenaline.
Metabolic - blood glucose, lipolysis, muscle amino acids.
These changes represent the stress response to surgery which can 
be modified by analgesia, although even total pain relief may not 
decrease it significantly after major operation (122). A  new 
analgesic can be assessed by the effect it has on this response, 
although such studies are of less use when comparing individual doses 
of different drugs.
Respiratory parameters Painful incisions in the chest and abdomen 
inhibit respiratory activity leading to changes in arterial blood 
gases and respiratory function tests. Measurement of respiratory 
function by spirometry after operation may give useful information 
about pain intensity (191), and peak expiratory flow rate is often 
used for this purpose.
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Arterial blood carbon dioxide tension Pain may lead to 
hyperventilation which may be prevented by effective analgesia. 
Opioids given after surgery, as a consequence of their respiratory 
depressant effect, may increase PaC02 , and this may be avoided by 
using alternative analgesics (37,38,84).
Autonomic responses Heart rate, blood pressure, skin conductance 
and temperature have been correlated with painful stimuli, but these 
responses habituate rapidly and are affected by many factors other 
than pain, including anxiety.
Electrophvsiological methods Measurements of cortical evoked 
potentials can be used to assess experimentally applied pain stimuli, 
but such techniques are difficult to apply after surgery (192).
2.2.4 The assessment of pain relief
Verbal rating scales These can be completed by the patient and 
the observer using the four point scale:
0 = no pain relief
1 = mild pain relief
2 = moderate pain relief
3 = complete relief
Visual analogue scales As with pain intensity, pain relief can be 
assessed using VAS marked 'no relief' and 'complete relief' at either 
end.
Additional analgesia The effect of a study drug can be assessed 
by the patient's additional requirements for analgesia. Patient 
controlled analgesia (PCA) allows access to intravenous opioids on 
demand, while the study drug is given by a different route. PCA 
demands and opioid usage then reflect the efficacy of the study drug.
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This method has been used successfully to assess intramuscular NSAIDs 
after surgery (84). Alternatively the requirement for additional 
analgesia administered by nursing staff may be recorded (41).
2.2.5 Derived scores These are used when the effect of an 
analgesic is observed over a timed period, typically of 6 hours. If 
pain intensity scores are performed before (baseline) and at times 
after analgesic administration then pain intensity difference (PID) 
can be calculated as baseline pain minus the timed score. Over an 
assessment period PIDs can be added giving the summed pain intensity 
difference (SPID) for both VRS and VAS scores. Similarly timed pain 
relief scores can be summed over an assessment period to give a total 
pain relief score (TOTPAR). SPID and TOTPAR and the visual analogue 
equivalents are often used to compare analgesics after surgery 
(82,83).
2.2.6 The placebo effect There can be a significant placebo 
effect in pain studies (193), but it is not ethically acceptable to 
administer placebo injections in the presence of severe postoperative 
pain. It is possible to include placebo groups after surgery if 
alternative analgesia is provided by other means, for example by PCA 
(84,85).
2.3 Methods used in this thesis to assess pain and analgesia
In this thesis, the assessment of analgesic efficacy is based on 
the use of subjective rating scales for pain intensity and pain 
relief. In each study only one operation was used and the anaesthetic
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technique standardized. Patients were randomly allocated to 
treatments and studies were double-blind. To reduce variability one 
nurse-observer scored all the patients.
2.3.1. Observer assessment The observer scored pain intensity and 
relief using the four point scales:
0 = no pain 0 = no pain relief
1 = mild pain 1 = mild relief
2 = moderate pain 2 = moderate relief
3 = severe pain 3 = complete relief
In making these assessments, the observer took account of the 
patient's demeanour and spontaneous comments. The observer scored 
pain and analgesia before the patient made any assessments.
In the pilot study of the effect of ketorolac after 
cholecystectomy (Chapter 3.1), the simpler three point scale was 
used:
0 = no pain
1 = pain which is not bad enough to need medication
2 = pain which needs relief
2.3.2 Patient assessments The patients used the same four point 
VRS, and also completed VAS for pain intensity and pain relief. Both 
forms of rating scale were used to allow for the difficulty patients 
experience in completing VAS immediately after operation.
In the study of ketorolac as an adjunct to morphine after 
thoracotomy (Chapter 4), the patients scored pain both at rest and 
upon taking a deep breath.
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2.3.3 Derived scores When repeated assessments were made of 
individual doses of study medication (Chapter 3.2), SPID and TOTPAR 
and the visual analogue equivalents were calculated and used for 
comparison.
2.3.4 Demand analgesia When PCA was used (Chapter 4) patient 
morphine consumption was analysed and used to compare the study 
groups. In the other studies requirements for rescue analgesia and 
the time between doses of study medication were used as indicators of 
analgesic efficacy (Chapter 3.2).
2.3.5 Overall assessments The patients and the observer gave 
their overall assessments of analgesia as poor/fair/good/very good.
2.3.6 Instruction of patients On the day before surgery, each 
patient was carefully shown how to use the VRS and VAS for pain 
intensity and pain relief, and sample scorecards were left by the 
bedside so that they could become fully accustomed to them before the 
study began. The subjects were also told that they should make their 
own assessments, without any influence from the observer or other 
staff.
2.3.7 Patient pain intensity and pain relief scorecards Booklets 
of cards were used for patient assessments. At the beginning of the 
study each patient was given a booklet for pain intensity and one for 
pain relief, coloured pink and yellow, respectively. On each card 
there was a VAS and a VRS for pain or pain relief. After each 
assessment, the completed card was torn out of the booklet so that 
the patient could not see the previous scores made.
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2.3.8 Other assessments used The rate and reason of premature 
withdrawal from study groups was examined.
2.4 Methods used to assess platelet function and haemostasis
2.4.1 Introduction The effect of ketorolac and diclofenac on 
platelet function was assessed in patients using skin bleeding time, 
whole blood in vitro platelet aggregation, and surgical blood loss.
In a volunteer study of the possible haemostatic interaction between 
ketorolac and dextran-70, additional tests were done, including 
thromboxane production, coagulation factors, and tissue plasminogen 
activity.
Platelet aggregation It has recently become possible to study in 
vitro platelet aggregation in whole blood (194,195). This may be more 
physiological than traditional turbidometric methods using platelet- 
rich plasma, as the platelets are left in their natural milieu 
surrounded by red and white cells that can influence the aggregatory 
response (196,197). Aggregation induced by collagen and arachidonic 
acid is dependent mainly upon platelet thromboxane production, and 
can be inhibited NSAIDs.
Platelet thromboxane production Thromboxane A 2 is produced by 
platelet cyclo-oxygenase and promotes aggregation and adhesion, which 
are necessary for primary haemostasis. Thromboxane A 2 is rapidly 
metabolized in the blood and measurement of the stable product 
thromboxane B2 is a more reliable indicator of production (4,8).
Dextran The mechanism of action of dextran is not completely 
known, but it may involve haemodilution and improved blood flow, 
impairment of haemostasis including an anti-platelet effect, a fall 
in factor VIII and increased tissue plasminogen activity (198,199). 
Unlike NSAIDs, dextran is not thought to affect thromboxane synthesis
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but rather reduces platelet adhesiveness by a mechanism which may 
involve the endothelial response to injury. The effect of dextran, 
alone and in combination with ketorolac, was investigated using whole 
blood thromboxane B2 , von Willebrand antigen, factor VIII activity, 
and tissue plasminogen activator activity.
Von Willebrand factor is important in primary haemostasis and is 
produced in the endothelium and the liver. Endothelial damage leads 
to release of von Willebrand factor, and platelets adhere to it, 
producing primary haemostasis. Von Willebrand factor is a good 
measure of endothelial injury or stimulation. Dextran may stimulate 
the endothelium in a nonspecific manner, and in this thesis von 
Willebrand antigen was measured to assess that effect. Von Willebrand 
factor also has a separate role as a carrier protein for factor VIII, 
and was previously termed factor VIII related antigen (91).
Factor VIII is produced in the liver and is important in 
coagulation, and may be affected by dextran (198). Stimulation of the 
endothelium by dextran could also affect factor VIII by increasing 
the release of the carrier protein, von Willebrand factor. To assess 
these actions of dextran, factor VIII coagulant activity was 
measured.
Tissue plasminogen activator increases fibrinolysis by promoting 
the conversion of the precursor plasminogen to active plasmin (91).
In this thesis, tissue plasminogen activator antigen was measured to 
investigate the possibility that dextran may increase the activity of 
this substance (198).
2.4.2 Skin bleeding time This in vivo test of platelet function 
was performed on the forearm by the modified method of Ivy (200,201) 
using a Simplate-II bleeding time device (Organon Teknika) to
t
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standardize the length and depth of incision. The Simplate-II is a 
sterile, disposable, device used to make uniform incisions for the 
bleeding time test. The spring-loaded blades are contained in a 
plastic casing, and, when triggered on the forearm, make two 
incisions in line, 5mm long by 1 mm deep.
The subject was seated comfortably and the arm supported with the 
volar aspect of the forearm exposed. The incision site was selected 
and cleaned with an alcohol swab. A sphygmomanometer cuff was applied 
to the upper arm and inflated to 40 mmHg, and maintained at that 
pressure. The Simplate-II device was placed firmly on the forearm, 
without pressing, perpendicular and distal to the antecubital fossa. 
The device was triggered, and a stopwatch timer simultaneously 
activated. Each 30 seconds the flow of blood was observed by blotting 
with a Whatman No.l filter paper disc, taking care not to disturb the 
platelet plug. The timer was stopped when blood no longer stained the 
filter paper. A  butterfly bandage was applied to the wound to 
approximate the skin edges. The bleeding time was measured for each 
incision and the mean recorded. The upper limit of normal for skin 
bleeding time using this technique is 10 minutes (201).
In this thesis skin bleeding time was measured before and one 
hour after intramuscular injection of ketorolac or diclofenac, and 
any change observed. Most of the skin bleeding times were performed 
by the author, and in every case the same observer did all the tests 
in any one subject.
2.4.3 Platelet aggregation This was studied in vitro using a 
Clay-Adams Ultra-Flo 100 whole blood platelet counter (195,202). 
Spontaneous, collagen induced (2^g ml-*, Semmelweiss), and 
arachidonic acid (0.5 mmol litre- *, Sigma) induced aggregation was
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observed. A venous blood sample was taken, anti-coagulated with 3.8% 
trisodium citrate, and taken directly to the laboratory so that it 
could be studied within one hour. From each sample a red cell count 
was first determined and dialled into the whole blood platelet 
counter. A  10 jilitre aliquot was withdrawn and the baseline platelet 
count determined (100%). The aggregating agent, if used, was then 
added and the sample stirred at a constant 1000 rpm and 37°C. Further 
aliquots were taken at five and ten minutes for spontaneous 
aggregation, and one, three, and five minutes for collagen and 
arachidonic acid induced aggregation. The platelet count at each 
sample time was determined as a percentage of the baseline count. 
Collagen and arachidonic acid induced aggregation depend to a large 
extent on thromboxane production, but spontaneous aggregation does 
not.
Using this technique, aggregation is measured by the percentage 
fall in the number of free platelets from baseline during the 
observation period. These studies were performed before and one hour 
after the administration of ketorolac or diclofenac, and any change 
in aggregation noted.
2.4.4 Blood loss Surgical blood loss was estimated by weighing of 
swabs and suction loss at operation. When surgical drains were 
positioned, as after thoracotomy, any continuing postoperative 
bleeding was recorded.
2.4.5 Whole blood thromboxane B 2 (TXB2 ) generation Aliquots of 1 
ml of fresh venous blood were left to clot spontaneously at 37°C for 
30 minutes. The specimen was centrifuged at 3,000 rpm for 15 minutes 
at 4°C, and the serum then analysed for TxB£ by radioimmunoassay
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(203). To increase yield, TxB£ was first converted to the methyl 
oxime form by incubation with methoxyamine hydrochloride. Tritiated 
thromboxane B£ was obtained from Amersham International, and antisera 
to thromboxane B2 was raised in the University of Edinburgh (203).
2.4.6 von Willebrand Factor antigen (vWF:Ag) An aliquot of venous 
blood was anticoagulated with 3.2% trisodium citrate and vWF:Ag 
measured by the Laurell "rocket" electroimmunoassay (204), a method 
used for quantitative analysis of charged proteins. The sample 
containing the protein (vWF:Ag) is placed in a well in an agarose gel 
containing antibody, and an electrophoretic field induces migration 
of antigen which reacts with the antibodies to form precipitation 
zones like ascending rockets, hence the name. The final position of 
the precipitation zone depends on the amount of antigen present in 
the sample.
2.4.7 Factor VIII coagulant activity (FVIIIc) The activity of 
FVIII was measured by a modification of the kaolin clotting time 
using anticoagulated venous blood (205). An aliquot of the plasma to 
be tested is mixed with haemophilic plasma preincubated with kaolin, 
calcium is added, and the specimen tilted continually until clot 
appears. The correction of the clotting time of the haemophilic 
plasma measures the FVIIIc of the test sample.
2.4.8 Tissue plasminogen activator antigen (tPA antigen) A  double 
monoclonal antibody enzyme linked immunosorbent assay (ELISA) was 
used to measure total plasma tPA antigen (206). The mouse antibodies 
to tPA antigen were raised in the University of Edinburgh.
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Horseradish peroxidase (Sigma) was conjugated with one antibody, and 
the reaction of this with tetramethylbenzidine substrate (Sigma), 
measured by absorption of light, forms the basis of the assay.
2.5 Methods used to assess renal function
2.5.1 Plasma urea, creatinine and electrolytes This was performed 
by routine analysis in the clinical chemistry laboratory of the Royal 
Infirmary of Edinburgh. Normal ranges for this laboratory are: sodium 
132-144 mmol/litre; potassium 3.3-4.7 mmol/litre; urea 2.5-6.6 
mmol/litre; creatinine 55-150 ^mol/litre.
2.5.2 Urine flow rate and electrolyte excretion When patients 
were catheterised, urine flow rate and sodium and potassium excretion 
were calculated, by normal laboratory methods.
Urinary clinical chemistry was performed as a batch at the end of 
the study. Aliquots of the urine collection were frozen at -20°C 
until the analysis was performed.
2.5.3 Creatinine and free water clearances Creatinine clearance 
and free water clearance (urine flow rate - osmolar clearance) were 
also calculated.
2.5.4 Renal prostaglandin generation The renal production of 
prostacyclin, PGI2 , can be assessed by measuring the urinary 
concentration of the stable metabolite 6-keto-PGFpa (207,208). PGI2 
produced in tissues normally breaks down spontaneously to 6-keto- 
PGFia , which is then rapidly metabolised in the systemic circulation 
to the main urinary product 2,3 dinor-6-keto-PGFia (4,8,207). 6-keto- 
PGF^a can be used to investigate renal production of PGI2 since it is
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not further metabolised in the urine (207). It is accepted that 
measurement of 6-keto-PGFia and 2,3 dinor 6-keto-PGFia reflect 
renal and systemic prostacyclin production respectively (209).
Urinary 6-keto-PGFia concentration was measured from samples 
collected and stored as described above. Knowing the urinary volume 
produced in a given time, the production per minute of 6-keto-PGFia 
was calculated.
Measurement of urinary 6-keto-PGFia concentration was by 
radioimmunoassay (210). Aliquots of urine were collected and frozen 
at -20°C until the analysis was performed in a batch. Urine was 
acidified and the prostaglandin extracted into ethyl acetate. The 
assay used a double-antibody technique as the separation method. The 
specific antibody for 6-keto-PGFia was raised in the Department of 
Pharmacology of the University of Edinburgh, and tritiated 6-keto- 
PGFia was obtained from Amersham International Ltd. The inter- and 
intra- assay coefficients of variation for the assay were 15% and 11% 
respectively.
2.6 Study details
2.6.1 Ethics committee approval and consent The studies 
comprising this thesis were assessed and approved by the Lothian 
Health Board anaesthetics ethics committee. Informed, written, 
consent was requested from patients and volunteers before they were 
enrolled. In each case consent was witnessed by the author.
2.6.2 Patient enrolment and exclusion criteria Patients were 
enrolled from the surgical lists of the Royal Infirmary, the Western 
General Hospital, and the Thoracic Unit of the City Hospital, 
Edinburgh. Exclusion criteria were a history of ulcer disease,
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bleeding tendency, asthma, allergy, aspirin intolerance, age less 
than eighteen years, recent analgesic administration, and alcohol or 
narcotic abuse.
2.6.3 Study blinding and randomization All the studies were 
performed in a double-blind randomized manner so that neither the 
patient nor the observer knew which drug had been given.
Randomization was by means of tables of random numbers used to 
allocate treatments. Upon enrolment, each patient was allocated a 
study number and corresponding treatment. Numbered envelopes 
containing the treatment given to each patient was held by the 
hospital pharmacy in the form of a randomization code, and were only 
referred to if an adverse event occurred. At the end of each study 
the code was broken and the data analysed.
2.6.4 Data collection and recording Subject record books were 
used for each study in the thesis, and all data were written in these 
for later analysis. When patient controlled analgesia was used a 
printout was made each 24 hours from the Abbott PCA plus machine 
using a hand-held printer (Epson P-40) and the hourly morphine usage
was then transcribed into the study record book. Pain and pain relief
scores were made in separate record books which were arranged so that 
the subject and observer could not see the last score they had made.
2.7 Statistical design, data analysis, and presentation
2.7.1 Statistical power In the design of the efficacy studies, an 
assessment of statistical power was made so that an adequate number 
of patients were included. A nomogram was used which related power,
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total study size, the standarized difference, and the significance 
level (211). The standarized difference is the smallest difference 
which would be clinically relevant, divided by the estimated standard 
deviation of the sample. A  discussion of the estimation of 
statistical power is included in each chapter where appropriate.
2.7.2 Statistical tests (212,211,183) All tests were two-tailed 
and the significance level was set at 5%.
Categorical data were analysed by Fisher's exact or Pearson's 
Chi-square test where appropriate.
Comparisons of nonparametric data from two groups were made using 
the Mann-Whitney U test, for unpaired samples. When there were more 
than two groups the Kruskal-Wallis test was used.
Paired and unpaired t-tests were used to compare parametric data 
from two treatment groups. Analysis of variance was used when there 
more than two groups, or when repeat observations were made on the 
same subjects. In Chapter 4, one-way analysis of variance was used to 
analyse data from different groups. In Chapter 5.4, two-way analysis 
of variance was used when different treatment effects were obtained 
from the same volunteers. When appropriate, 95% confidence intervals 
were calculated (95% Cl).
All VRS, and derived scores including SPID, TOTPAR and visual 
analogue SPID and TOTPAR were analysed by nonparametric methods. In 
chapter 4.1, VAS were analysed using analysis of variance.
2.7.3 Calculation All statistical calculations were performed by 
the author using the programme 'Minitab' (version 6.2) (213) on an 
IBM-compatible personal computer.
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2.7.4 Presentation of results Demographic data are summarized by 
mean (SD), and other parametric data by mean (SE). Nonparametric data 
are represented by median (range).
2.7.5 Construction of figures The data were entered into the 
graphics programme 'Slidewrite plus' (Advanced graphics software). 
Figures were then produced on a Hewlett-Packard LaserJet II printer.
2.8 Classification of adverse events
An adverse event was taken to mean any undesirable occurrence 
during the study, and was not necessarily drug related.
An adverse drug reaction was defined as any effect of the drug 
not of therapeutic, diagnostic, or prophylactic value (88).
A 'serious' reaction was a fatal, life-threatening, disabling, or 
incapacitating adverse event (88). Other adverse reactions were 
described as 'minor', and included reactions leading to premature 
withdrawal from the study.
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CHAPTER 3 
KETOROLAC COMPARED WITH MORPHINE
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3,1 A  single dose pilot study of ketorolac 30 mg and morphine 10 mg
after cholecystectomy
3.1.1 Introduction Although ketorolac had been studied as a 
postoperative analgesic, little work had been done concerning the 
efficacy of the drug when used immediately after surgery. In this 
investigation the analgesic effect of ketorolac was assessed in the 
immediate postoperative period after upper abdominal surgery 
(cholecystectomy). Ketorolac is a relatively new analgesic, and, 
before a large study was embarked upon, a single dose pilot study of 
twenty patients was first performed to assess the efficacy and safety 
of intramuscular ketorolac.
3.1.2 Methods
Twenty patients undergoing elective cholecystectomy for 
gallstones were studied.
Anaesthesia After premedication with oral temazepam 20 mg, 
anaesthesia was induced with intravenous thiopentone and maintained 
with halothane, enflurane, or isoflurane in an oxygen, nitrous oxide 
mixture. Tracheal intubation was facilitated with intravenous 
suxamethonium. The lungs were ventilated artificially and vecuronium 
or atracurium given intravenously to achieve muscle paralysis. 
Neostigmine with atropine was given to antagonise the neuromuscular 
block. No analgesics were used other than study medication. 
Subcutaneous heparin (5,000 iu with premedication) was given 
electively at the time of premedication to all patients as 
prophylaxis against deep venous thrombosis.
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Study design This was a double-blind, single dose, comparison of 
two treatment groups: ketorolac tromethamine 30mg and morphine 10 mg. 
Patients were allocated randomly to receive a single intramuscular 
dose of ketorolac or morphine. Upon enrolment, the patient was 
allocated a study number and a numbered ampoule containing either 
ketorolac 30 mg or morphine 10 mg. The anaesthetist in charge of the 
patient gave the injection to the vastus lateralis muscle using a 23 
gauge needle, thirty minutes after induction of anaesthesia.
Efficacy
Pain Two observers independently scored the patient’s pain each 
thirty minutes for up to four hours from the time of study drug 
administration. Scores were:
0 = no pain
1 = pain which is not bad enough to need analgesia
2 = pain which needs relief.
If the patient was still anaesthetised at an observation time a 
score of 0 was recorded. If a score of 2 was given then morphine 
rescue analgesia was administered. If the patient required rescue 
analgesia before the end of the four hour study period then a score 
of 2 was recorded for each of the remaining observation times.
Each patient was therefore assessed eight times by two observers 
over a four hour period producing a total pain score which ranged 
from 0 (no pain) to 32 (required rescue analgesia within thirty 
minutes of the study drug).
Time to next analgesia The time from administration of the study 
drug to the next analgesic was recorded to the nearest half hour.
Overall pain score Each observer and each subject (next day) 
assessed the overall quality of analgesia as very good; good; fair; 
poor.
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Side-effects All side-effects were noted including nausea, 
vomiting, and injection site discomfort. Operative blood loss was 
measured by weighing swabs and measuring the suction loss.
Statistical Analysis Patient details are summarized as mean 
(SD), for other parametric data mean (SE) are given and between group 
comparisons made using unpaired t tests. For the pain scores median 
(range) are given, and the Mann Whitney U test used to compare the 
groups.
3.1.3 Pilot study results
Patient data 20 patients entered the study. The groups did not 
differ significantly with respect to age 52.4(9.7) year ketorolac, 
54.7(8.9); weight 66.1(16.7) kg ketorolac, 73.6(15.6) morphine; 
height 165 (8.8)cm ketorolac, 164(8.2) morphine; and sex 
distribution, male/female 4/6 and 3/7 respectively.
Pain Scores There was no statistical difference between the 
observer pain scores from the two groups (P=0.63). The median score 
in the ketorolac group was 19.5 (range 8-28), and in the morphine 
group 22 (0-32).
Time to next analgesia The mean time in minutes to next 
analgesia in the ketorolac group was 156, and 138 in the morphine 
group (P= 0.62).
Observers' overall assessments The two observers agreed in each 
case in their overall assessments. In the ketorolac group the 
assessment of-analgesia was very good 2, good 2, fair 4, and poor 2. 
The assessment in the morphine group was very good 1, good 4, fair 0, 
and poor 5. The ketorolac group received better overall assessments 
than the morphine group (five of whom were classed as having poor 
analgesia).
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Patients' overall assessment The patients classed ketorolac as 
very good 2, good 4, fair 3, and poor 1. Morphine was assessed as
very good 0, good 3, fair 3, and poor 4.The observers and the
subjects agreed in their assessments apart from one subject in the 
ketorolac group who felt that his analgesia was very good whilst the 
observers felt it was poor.
Blood loss The mean loss in the ketorolac group was 231(55) ml, 
and in the morphine group 213(47), (P=0.86). One patient in each 
treatment group had a higher than normal blood loss (ketorolac 695
and morphine 595 ml). The patient in the ketorolac group had a very
inflamed gall bladder bed, and the patient receiving morphine had 
adhesions due to previous surgery.
Adverse events There was no report of continuing injection site 
pain. One patient in each group required treatment with cyclizine for 
nausea. One subject who had morphine became heavily sedated, although 
this did not require specific treatment.
3.1.4 Discussion In this pilot study, a single intramuscular 
dose of ketorolac 30 mg given during surgery gave analgesia which did 
not differ from that of morphine 10 mg. Pain scores, time to next 
analgesia, and patient and observer overall assessments did not 
differ for ketorolac and morphine. Operative blood loss was not 
significantly increased by the NSAID. However, there was a marked 
variation between patients in pain intensity and in requirements for 
additional analgesia, even after the same operation. This meant that 
any further study comparing ketorolac with morphine would have to be 
large enough to take account of the interindividual differences seen 
in this pilot study.
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On the basis of this pilot study, it was felt appropriate to 
proceed with a larger investigation comparing ketorolac with morphine 
after cholecystectomy.
3.2 A  multiple dose study of ketorolac 30 mg versus morphine 10 mg 
intramuscularly after cholecystectomy
3.2.1 Introduction This study was designed to pursue the 
promising results of the pilot study and examine in greater depth the 
efficacy and safety of multiple doses of intramuscular ketorolac 30mg 
compared with morphine lOmg after cholecystectomy. Previous studies, 
giving good results, had not examined the effect of ketorolac 
immediately after surgery, but had been performed up to a day 
afterwards (82,83). The timing of an analgesic study after operation 
may be important, since investigations using intravenous lysine 
salicylate had found that it was unsuitable for use in the presence 
of severe pain present immediately after operation (36), although it 
was effective later (35). The aim of this study was to examine the 
efficacy of intramuscular ketorolac in comparison with morphine both 
immediately after surgery and also later in the postoperative period.
3.2.2 Methods
Patient selection and exclusion criteria One hundred male and 
female patients undergoing elective cholecystectomy were studied. The 
exclusion criteria and anaesthetic technique were the same as the 
pilot study.
Study design A double-blind, multiple dose, parallel group 
comparison of two treatments; ketorolac tromethamine 30mg and 
morphine 10 mg. Patients were randomly allocated to receive ketorolac
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or morphine (fifty in each group) in blocks of ten. The two 
analgesics were supplied in identical 1 ml amber coloured ampoules in 
boxes of eight, numbered 1 to 100. Each patient was allocated a study 
number, and received all eight doses from that box.
Administration of analgesia The first dose was given to the 
vastus lateralis muscle at induction of anaesthesia by the 
anaesthetist, using a 23 gauge needle. Doses were then given by the 
ward staff on patient demand, up to two hourly with a maximum of six 
doses in twenty four hours. Each patient could receive eight doses of 
study medication and the study lasted up to forty-eight hours. If 
analgesia was inadequate then rescue medication (morphine) was given 
at the discretion of the nurse, and the patient continued in the 
study.
Efficacy Assessments were made on the second dose of study 
medication (ie immediately after surgery, day 1) and on a dose on the 
morning of the next day (day 2). The patient and an independent 
nurse-observer scored pain intensity separately before injection, and 
pain intensity and pain relief at 0.5, 1, 2, 3, A, 5, and 6 hours. If 
the patient required further analgesia, or fell asleep in the six 
hour study period, then the last score recorded was used for the 
remaining observation times.
Pain scores Scores were made by the same nurse-observer. The 
patients gave assessments by verbal rating scales and visual analogue 
scales.
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Pain intensity scores Pain intensity was scored by the nurse and 
the patient on a four point VRS:
0 = no pain
1 = mild pain
2 = moderate pain
3 = severe pain
The patient also completed 10cm VAS for pain, (0-no pain to 
lOcm-worst possible pain).
Pain relief scores The observer and the patient scored pain 
relief on a four point VRS:
0 = no relief
1 = slight
2 = moderate
3 = complete relief
The patient also completed VAS for pain relief (0-no relief to 
lOcm-complete relief).
Derived scores Pain intensity differences (PID) were calculated 
by subtracting the scores from the baseline score. The seven PID from 
the six hour observation periods were added together to give summed 
pain intensity differences (SPID). SPID were derived for the observer 
and patient for days 1 and 2. The visual analogue equivalent of SPID 
from the patient was calculated (visual analogue SPID). Total pain 
relief scores (TOTPAR) and the visual analogue equivalent were 
calculated (visual analogue TOTPAR) by adding the scores from each 
observation time together.
Intervals between injections We recorded the time in minutes 
between the second dose (ie immediately after surgery) and the next 
analgesic injection as a further measure of efficacy.
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Morning assessments. On the morning after surgery (day 2) and 
the next morning (day 3) the patient was asked if he or she had slept 
well, if the pain control was satisfactory, and about any unpleasant 
dreams. Oral temperature was noted at this point.
Final assessment. At the end of the study both patient and 
observer independently gave an overall opinion of analgesia as very 
good/ good/ fair/ poor.
Oral intake and intravenous fluids The time in hours was 
recorded from the end of surgery to established oral intake and to 
removal of the intravenous infusion.
Completion rates and early withdrawal Each subject completed the 
study if all eight doses of medication over days 1 and 2 were 
received. Completion rates were compared between the groups, and 
reasons for withdrawal noted.
Injection site discomfort The subject rated pain on injection as 
none/ minimal/ moderate/ severe.
Adverse events All were recorded, and venous blood was sampled 
for haematological and biochemical analysis before and after the 
study period.
3.2.3 Statistical design and analysis The pilot study had 
indicated that there could be a wide variation between patients in 
pain experience after cholecystectomy, and this study was designed' to 
be large enough to compensate for that.
In comparing the two analgesics, the most important measurement 
of efficacy was the SPID. As the pain scores were on an ordered four 
point scale, pain intensity difference at each assessment could be -3 
to 3. SPID over six hours (seven assessments) could range from -21 to 
21, with a mean of zero and standard deviation of approximately 7.
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Taking a significance level a of 5%, a difference between the 
analgesics in SPID of 4 (approximately 10%) could be detected with a 
power of 80% if the total sample size was one hundred patients (211).
For demographic data mean (SD) are given. For other data median 
and range are given, and nonparametric statistical tests used. 
Categorical data were analysed using Fisher's exact or Pearson's Chi- 
square test. Ordinal and interval data were analysed using the Mann- 
Whitney U test.
3.2.4 Enrolment rate and exclusions (table 1) To enrol one 
hundred patients into this study, an attempt was made to recruit 
every person having elective cholecystectomy in the Royal Infirmary 
and the Western General Hospital of Edinburgh over a period of time, 
although it proved impossible to study all patients available to us 
at a given time. Of the patients contacted, a large number, 113 were 
found to be unsuitable on the basis of exclusion criteria (table 1), 
meaning that 213 patients had to be approached before the study could 
be completed. The main reasons for exclusion were peptic ulcer 
disease, asthma and chronic obstructive airways disease, involvement 
in other clinical studies (perhaps to be expected in teaching 
hospitals), and poor general medical condition (most often due to 
ischaemic heart disease). Of all the patients approached, only four 
declined to participate after the nature of the study had been 
explained to them. It took fourteen months to complete the study.
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Reason Number
Peptic ulcer disease 16
As thma 9
Severe COAD 12
Aspirin sensitivity 3
Opiate sensitivity 1
Concomitant medication 14
Recent opiate intake 4
Alcohol abuse 2
Psychiatric illness 5
Involved in other clinical studies 13
Patient declined 4
Unsuitable for medical reasons 30
Total 113
Table 1 Reasons for exclusions from the cholecystectomy study.
3.2.5 Results
Patient details (table 2) The two treatment groups did not 
differ significantly with respect to sex, age, height, weight, 
position of incision, and duration of surgery.
Efficacy (table 3)
Baseline pain intensity Pain intensity did not differ 
significantly for the two groups on days 1 and 2. The patients tended 
to score pain as "severe" on day 1 and "moderate" on day 2.
Performance of assessments On day 1, only 70% and 40% of the 
patients could complete the VRS and VAS assessments respectively. On 
day 2, all the patients remaining in the study could do both VRS and 
VAS assessments.
Pain intensity scores Observer and patient SPID were 
significantly less for ketorolac than for morphine on day 1. On day 2 
ketorolac and morphine results did not differ.
Visual analogue SPID was less for ketorolac on day 1, but the 
difference was not statistically significant. On day 2 there was no 
difference.
Pain relief scores Observer and patient TOTPAR were 
significantly lower for ketorolac on day 1, but on day 2 there was no 
difference.
Visual analogue TOTPAR showed no difference between the drugs on 
either day.
Intervals between injections, and rescue morphine (table 4)
After the second dose of study medication, patients receiving 
ketorolac required repeat analgesia much sooner than those receiving 
morphine. In the first 24h of the study, the ketorolac group required 
more rescue medication than the morphine group. In the second 24h 
there was no difference between the groups.
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KETOROLAC 
M/F 17/33
Age(yr) 53.5(14.2)
Height(cm) 166.2(9.9)
Weight(kg) 69.4(12.1)
Subcostal incision 39
Hidline incision 11
Duration(min) 86(3.9)
MORPHINE
13/37
52.3(14.9)
164(7.8)
67.3(12.8)
37
13
91(5.1)
Table 2 Details of the patients in the cholecystectomy study (mean, 
SD), incision site, and duration of surgery (mean, SE).
KETOROLAC MORPHINE P
BASELINE PAIN
Observer
Day 1 2 (1,3) 2 (2,3) 0.48
Day 2 2 (1,3) 2 (1,3) 0.18
Patient
Day 1 3 (2,3) 3 (2,3) 0.99
Day 2 2 (1,3) 2 (1,3) 0.2
Patient visual analogue
Day 1 81 (52,100) 80 (63,100) 0.42
Day 2 52 (10,100) 64 (9,99) 0.13
SPID
Observer
Day 1 0 (-7,12) 7 (0,14) 0.0001
n 48 45
Day 2 7 (0,10) 6 (-5,13) 0.9
n 37 38
Patient
Day 1 0 (-7,11) 6 (0,13) 0.003
n 32 30
Day 2 1 (-5,13) 5 (-11,13) 0.21
n 37 38
Patient visual analogue
Day 1 7 (-81,427) 109 (-112,420) 0.11
n 19 18
Day 2 112 (-136,470) 132 (-339,522) 0.41
n 37 38
TOTPAR
Observer
Day 1 1.5 (0,14) 13 (0,20) 0.0001
n 48 45
Day 2 13.5 (0,21) 12.5 (2,20) 0.79
n 37 38
Patient
Day 1 0 (0,14) 6 (0,20) 0.029
n 32 30
Day 2 12 (0,21) 12 (2,16) 0.62
n 37 38
Patient visual analogue
Day 1 46 (0,532) 86 (0,458) 0.24
n 19 18
Day 2 320 (0,70) 373 (58,630) 0.61
n 37 38
Table 3 Ketorolac after cholecystectomy. Baseline pain, and SPID and 
TOTPAR over 6 hours, by the nurse observer and the patient. Visual 
analogue scale in mm. Median (range). P: Mann-Whitney U test. For the 
observer, n is the number of patients studied at each time. For 
patients, n is the number able to perform each assessment at each 
point in the study.
KETOROLAC MORPHINE P
Time (min) 72.5 (15,1125) 207.5 (20,915) 0.0001
Morphine(mg)
Day 1 10 (0,36) 0 (0,55) 0.003
Day 2 0 (0,10) 0 (0,10) 0.9
Table 4 Ketorolac after cholecystectomy. Time from the second 
intramuscular dose to the next injection and daily requirements for 
rescue morphine. Median (range). P: Mann-Whitney U test.
Morning assessments (table 5) The patients in the two groups 
reported similar satisfaction with overnight sleep and pain relief. 
There was no difference in the incidence of psychological 
disturbances or pyrexia.
Final Assessment (table 6) There was no statistical difference 
in the overall opinion of the patients or observers of the study 
medication. Nevertheless six patients who received ketorolac 
described their analgesia as poor.
Oral intake and intravenous fluids (table 6) The time until oral 
intake recommenced was not different between the groups, but the 
morphine group received intravenous fluids for longer.
Completion rates and early withdrawal (table 6) The completion 
rate did not differ significantly for the two groups, although more 
patients did withdraw in the ketorolac group. The most common reason 
for early withdrawal was that parenteral analgesia was no longer 
required and oral therapy was started. Failure of analgesia accounted 
for seven and two withdrawals from the ketorolac and morphine groups 
respectively.
Injection site abnormalities and pain (table 6) There was no 
difference in the incidence of injection site abnormality or pain on 
injection between the groups.
Adverse events Ketorolac produced more nausea (P=0.005) and 
vomiting (P=0.05) on the day of operation, but not on the day after 
(P=0.73, and 0.85 respectively). Morphine was associated with a 
higher incidence of drowsiness on days 1 (P=0.0001) and 2 
(P=0.007). Mild dyspepsia was more common with ketorolac (7 patients) 
than morphine (2 patients), although this did not reach statistical 
significance (P=0.1, Fisher's Exact test).
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KETOROLAC MORPHINE P
Day 2
Satisfactory sleep?
Y/N 26/20 25/22 0.74
Satisfactory analgesia?
Y/N 36/10 38/9 0.76
Psychological disturbances?
Y/N 8/38 8/39 0.96
Temperature>38°C?
Y/N 2/44 4/43 0.41
Day 3
Satisfactory sleep?
Y/N 19/7 26/7 0.61
Satisfactory analgesia?
Y/N 24/2 32/1 0.42
Psychological disturbances?
Y/N 2/24 2/31 0.80
Temperature>38°C?
Y/N 0/26 2/31 0.20
Table 5 Ketorolac after cholecystectomy. Morning assessments on the 
second and third study days.
KETOROLAC MORPHINE P
Patient
Very good 21 23 0.22
Good 17 16
Fair 3 4
Poor 6 0
Observer
Very good 22 21 0.91
Good 13 13
Fair 7 8
Poor 6 4
Oral intake (hr) 27.5 (18,50) 30 (20,112) 0.16
Infusion (hr) 48.5 (25,108) 51.5(26,200) 0.04
Completion rate
completed 19 27 0.16
withdrew 31 23
Injection site abnormality
Y/N 10/39 7/41 0.59
Pain on injection
None 35 36 0.65
Minimal 11 7
Moderate 3 4
Severe 0 0
Table 6 Ketorolac after cholecystectomy. Overall opinion of study 
medication, time to oral intake, duration of intravenous infusion, 
completion rates, and injection site abnormality and pain. Median 
(range).
Two patients from the ketorolac group and four from the morphine 
group were withdrawn because of adverse events. In the ketorolac 
group one patient was returned to theatre because of continuing blood 
loss; an obvious source was controlled. Another of the ketorolac 
group developed a chest infection. Two of the morphine group had 
excessive postoperative blood loss. One was returned to theatre, but 
no obvious bleeding vessel was found; the other required a blood 
transfusion only. Two of the morphine group developed chest 
infections; one also experienced excessive drowsiness which was 
treated with naloxone. No severe adverse events were reported.
Venous blood was sent for biochemical and haematological 
analysis before and after the study. No abnormal liver function tests 
or changes in haematology values were detected. Changes in urea, 
creatinine and electrolyte concentrations levels are presented in 
Chapter 6.
3.2.6 Discussion After cholecystectomy, ketorolac 30 mg gave 
significantly worse analgesia in the immediate postoperative period 
when compared with morphine 10 mg, but on the next day the effect of 
the two drugs did not differ. This was demonstrated by observations 
of pain intensity, pain relief, time to next injection, and overall 
assessment of analgesia. The baseline pain intensity in the immediate 
postoperative period was severe, and the next day it was moderate.
Our findings suggest that an intramuscular dose of ketorolac 30 mg is 
sufficient for the relief of moderate, but not severe pain.
The encouraging result of the pilot study was therefore not 
confirmed by this study. Whereas the pilot study indicated that 
ketorolac was safe to use and had an appreciable analgesic effect, it 
it was not sufficiently large or detailed to explore fully the
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difference between ketorolac and morphine analgesia. It was necessary 
to study a much larger number of patients to ensure that any 
differences between morphine and ketorolac could be detected.
Other observers found that ketorolac 30 mg was at least as 
effective as 12 mg of morphine in relieving moderate to severe pain 
after various operations, including major surgery (82,83). As these 
were single dose studies performed up to two days after surgery they 
should be compared with, and are similar to, our day 2 results.
Recently ketorolac 10 mg has been compared favourably with 
morphine 10 mg after gynaecological laparotomy (214). A  30 mg loading 
dose of ketorolac followed by 10 mg four hourly resulted in pain 
scores similar to those seen after morphine, although pain-relief 
scores were better with the opioid. Differences between that study 
and the one described here may account for the better performance of 
ketorolac after gynaecological surgery. These include the less 
painful surgical incision and the administration of an opioid 
premedication in the study of Powell and others (214). It is 
therefore possible that ketorolac could be used alone for less 
painful operations than cholecystectomy, especially if an opioid has 
already been given in theatre.
Our conclusion that ketorolac is unsuitable for the relief of 
severe pain is similar to that from studies on the analgesic effect 
of a parenteral formulation of aspirin. Lysine acetyl salicylate is a 
poor analgesic when compared with morphine as a bolus in the 
immediate postoperative period (36), but equivalent to morphine when 
given as an infusion over a period of time (35).
Although ketorolac was a poor analgesic in the immediate 
postoperative period, the ketorolac group expressed overall 
satisfaction with their analgesia, and only required a small dose of
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rescue morphine (10 mg) in the first twenty four hours and none the 
next day. Such results may indicate that the quality of ketorolac 
analgesia became similar to that of morphine after the initial 
postoperative period. A  morphine sparing effect of ketorolac, after 
abdominal surgery, has been documented before (84), and is further 
investigated in this thesis (Chapter 4).
Patients found it difficult to do VRS and, particularly, VAS 
assessments in the immediate postoperative period, confirming the 
value of an observer at that time (table 3). On the day after surgery 
the patients found it easy to perform the scores. Observers are 
therefore very useful in studies performed soon after surgery when 
much information could be lost if only patient scores were collected. 
The use of VAS immediately after surgery may be of limited value.
Ketorolac does not inhibit gut motility (62), and in this study 
the patients receiving ketorolac required intravenous fluids for a 
significantly shorter time, although the time to oral intake did not 
differ between groups. This may be important because ketorolac may 
also be available as tablets which could be used when the patient can 
take fluids. It was noted that many patients in this study required 
parenteral analgesia for only a short time after cholecystectomy.
Intramuscular ketorolac did not produce more injection site pain 
or abnormalities than morphine. Ketorolac given as repeated 
intramuscular injections does not increase serum creatinine 
phosphokinase levels, but diclofenac does (64). The muscular
discomfort produced by injections of diclofenac may not be a problem
with ketorolac.
Adverse reactions were minor. Although opioids are recognised to 
have an emetic effect, ketorolac was associated with more nausea and
vomiting on the day of operation than morphine. Other
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gastrointestinal side-effects were minor, ketorolac 30 mg 
intramuscularly resulted only in mild, transient, dyspepsia in 7 out 
of 50 subjects. Ketorolac 30 mg may not produce peptic ulceration 
when given for a short time after abdominal surgery. In view of the 
results of volunteer studies concerning the effect of ketorolac on 
gastric mucosa (149), this drug should not be given if there is a 
history of peptic ulceration. Drowsiness and sedation were persistent 
problems with morphine as could be predicted from work done on the 
psychomotor effects of ketorolac and opioids (64). There were no 
clinically relevant changes in liver function or haematology tests 
after repeated administration of ketorolac over two days.
Of all the patients approached for this study, more than 10% 
were excluded because of a history of peptic ulceration and asthma 
(table 1), and this may be a reflection of the fact that a 
considerable proportion of general surgical patients will have 
absolute contraindications to the use of NSAIDs.
3.2.7 Conclusion Although ketorolac was a useful parenteral 
analgesic after upper abdominal surgery, 30 mg intramuscularly was 
adequate only for the relief of pain of moderate intensity. 
Immediately after upper abdominal surgery when pain was severe, 
ketorolac alone was not sufficient and was inferior to morphine 10 
mg. The administration of ketorolac intramuscularly for two days 
after surgery did not produce any serious adverse effects.
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CHAPTER 4 
KETOROLAC AS AN ADJUNCT TO MORPHINE
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4.1 Intramuscular ketorolac in combination with intravenous
patient controlled analgesia after thoracotomy
4.1.1 Introduction The cholecystectomy study indicated that 
ketorolac may not be sufficient to relieve severe pain when used 
alone, but previous work has suggested that NSAIDs may still be a 
useful component of analgesia when treating severe pain when combined 
with relatively low doses of opioids. That is, NSAIDs may act as 
adjuncts and have an opioid sparing effect. After upper abdominal 
surgery continuous intramuscular infusions of ketorolac (1.5 or 3 
mg/hr) improve analgesia, reduce patient controlled opioid 
requirements, and are associated with less postoperative respiratory 
depression (84). Indomethacin has a morphine sparing effect after 
surgery also (38), and, when given by suppository, reduces pain 
scores and opioid requirements after thoracotomy when pain and 
opioids often impair respiratory function (41). The possible morphine 
sparing effect of NSAIDs is worthy of further study because not all 
investigations have had this result (49,50).
In this study carried out after thoracotomy, the potential 
benefits of giving regular intramuscular ketorolac in combination 
with intravenous patient controlled analgesia (morphine) were 
investigated.
4.1.2 Methods
Patient selection and exclusion criteria The subjects were 
elective admissions to the thoracic unit in the City Hospital, 
Edinburgh, for thoracotomy and resection of lung tumours. 75 patients 
(aged 18 to 75y) were enrolled after giving written informed consent.
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Anaesthesia and surgery Premedication was with intramuscular 
papaveretum and atropine (prophylactic subcutaneous heparin, 5000 iu, 
was given at the time of premedication). Anaesthesia was induced with 
intravenous thiopentone, and maintained with oxygen in nitrous oxide 
and enflurane. Tracheal intubation was facilitated with intravenous 
suxamethonium and muscle paralysis maintained with alcuronium. At the 
end of the operation, neostigmine with atropine was used to
antagonise residual neuromuscular blockade. Intercostal nerve blocks
were performed after induction of anaesthesia using bupivacaine 0.5% 
with adrenaline 1/200,0000. If opioid analgesia was required during 
surgery intravenous fentanyl was given. All patients had an 
intercostal incision for thoracotomy and lung resection.
Study design This was a double-blind randomized study of six 
hourly intramuscular injections of ketorolac 30 mg, ketorolac 10 mg, 
or placebo.
Upon enrolment, subjects were allocated a study number (1 to 75)
and a corresponding box of study medication containing nine ampoules
for intramuscular injection. The ampoules were identical (amber 
coloured, 1ml) and contained ketorolac 30mg, 10 mg, or placebo 
according to the randomization schedule.
Drug administration The first dose of study drug was given 
intramuscularly to the vastus lateralis muscle, using a 23 gauge 
needle, at the end of the surgical procedure before anaesthesia was 
reversed, and the remaining eight doses were given six-hourly 
thereafter. Administration of the study drug was delayed until the 
end of surgery because of concern about the effect of ketorolac on 
platelet function and haemostasis. The study ended two hours after 
the last injection, 50 hours after the first dose of study medication 
was given.
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Patient controlled analgesia In the postoperative period the 
subjects had access to intravenous morphine from a patient controlled 
analgesia (PCA) machine (Abbott Lifecare PCA plus). The pump was set 
to deliver a bolus of morphine 2mg on demand, with a lockout time of 
15 minutes. No background infusion was used. The use of patient 
controlled analgesia allowed the inclusion of an intramuscular 
placebo group in the study. If analgesia was inadequate then the PCA 
bolus dose of morphine was increased. During the two day study period 
the subjects were nursed and monitored in a high dependency unit.
Efficacy
Morphine usage The patient's requirements for morphine from the 
PCA machine were recorded hourly during the two day study period.
Pain scores Both the patient and one nurse observer independently 
assessed pain at set times during the study. Pain at rest and pain on 
deep breathing were recorded two hours after the first (day 1), fifth 
(day 2) and ninth (day 3) intramuscular injections of study drug. The 
intramuscular injections were given at six hourly intervals, meaning 
that pain assessments were performed at 2, 26, and 50 hours into the 
study which ended at the last assessment.
Each patient assessed pain at rest and during deep breathing by a
four point VRS (0 = no pain, 1 = mild, 2 = moderate, 3 = severe
pain), and by a 10 cm VAS (0 no pain to 100 mm worst possible pain).
One nurse observer independently scored the patients pain using 
the four point score described.
Overall score On the day after surgery (day 2) and the last day
of the study (day 3) the observer and the patient gave an overall
assessment of pain relief as 'excellent/good/fair/poor'. At the same 
time the patients reported whether they had slept well the previous 
night and whether their pain control had been satisfactory.
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Physiotherapist's score After thoracotomy, physiotherapy is an 
important part of the overall management of the patient. An 
unfortunate effect of opioids is that the sedation they produce 
together with their anti-tussive effect can impair the patient's 
compliance with physiotherapy. During this study the unit 
physiotherapist scored the ability of the subjects to comply as poor, 
fair, good, or excellent.
Withdrawal rate Patients were classed as withdrawing from the 
study if they did not receive all nine intramuscular injections of 
study drug. The time and reason for withdrawal were recorded.
Sedation score The observer assessed the subjects level of 
sedation using a four point score (0 awake and alert, 1 awake but 
drowsy, 2 asleep and easily rousable, 3 asleep and rousable only by 
physical stimuli). These assessments were done at the same time as 
the pain scores.
Respiratory rate and arterial blood gas analysis The patient's 
respiratory rate was recorded, and a sample of arterial blood taken 
(from an indwelling catheter) for analysis of oxygen and carbon 
dioxide partial pressures and hydrogen ion concentration. If the 
patient was receiving supplementary oxygen then this was noted, 
together with the concentration delivered. These assessments were 
made at the same times as the pain scores (2, 26, and 50 hours from 
the beginning of the study). Respiratory rates and arterial blood 
carbon dioxide tensions (PaCC^) were compared between the groups as a 
measure of respiratory effects.
Blood loss from chest drains The blood loss, if any, from the 
chest drain left at operation was measured on each study day.
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Return of gastrointestinal function In order to assess the 
recovery of bowel function the time in hours to the return of bowel 
sounds and the resumption of oral (fluid) intake was recorded.
Haematology. Biochemistry Venous blood was sampled and sent for 
haematological and biochemical analysis before surgery and on each 
study day.
4.1.3 Statistical design and analysis The primary variable under 
analysis in this study was the subject's morphine usage. From 
preliminary observations, we predicted that the expected mean value 
of this in the first twenty four hours would be around 60 mg with a 
standard deviation of 20 mg. A  difference of morphine usage between 
groups of about one third (20mg) would be clinically significant and 
has been found in similar studies after abdominal surgery with 
ketorolac (84) and after thoracotomy and abdominal surgery with 
indomethacin (41,38). A  difference of morphine consumption between 
groups of 20 mg could be detected with a statistical power of 75% if 
there were 25 patients per treatment group (211).
Analysis of variance and the Kruskal-Wallis test were used to 
test for differences between the three treatment groups (placebo, 
ketorolac 10 mg, and ketorolac 30 mg), as described in chapter 2.7.3. 
One way analysis of variance was used to analyse morphine consumption 
and VAS results. The Kruskal-Wallis test was used for other scores.
4.1.4 Results
Patient details and surgical procedure (table 7) 75 patients were 
enrolled, 25 to each group. The treatment groups did not differ 
significantly in age, height, or weight. The majority of patients 
were male, and the sexes were similarly distributed between the
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PLACEBO KlOmg
M/F 19/6 20/5
Age(yr) 60(9.5) 59.2(10.3)
Height(cm) 172(11.9) 170(7.5)
Weight(kg) 69.4(13.1) 68.5(13)
Pneumonectomy or
lobectomy 21 19
Segmental
resection 2 2
Removal of thoracic 
cyst 1
Thoracotomy, no
resection 1 4
K30mg
23/2
56.5(13.5)
170(9.3)
70(14.7)
17
2
2
4
Table 7 Details of the patients in the thoracotomy study and the 
surgical procedure. Mean (SD). KlOmg and K30mg are ketorolac 10 and 
30 mg respectively.
groups. All operations were performed via an intercostal incision. 
Surgery was most commonly pneumonectomy or lobectomy for carcinoma of 
the lung, in a few cases partial tumour resection was performed, but 
in 9 of the patients it was impossible to remove any lesion and only 
thoracotomy was carried out.
Efficacy
Morphine usage (table 8. figure 2) The rate of morphine usage was 
consistent with the predictions of the statistical design of the 
study. The mean morphine consumption by the placebo group was 61 mg 
(SD 18.4) in the first 24 hours.
There was no significant difference in the amount of morphine 
used by the three drug groups at any time during the study period, 
although the placebo group tended to require more on average than the 
ketorolac groups. At 24 hours, the placebo group had used an average 
of 8.4 mg more morphine than the ketorolac 10 mg group (95% Cl -8 to 
25 mg, P=0.12), and 6 mg more than the ketorolac 30 mg group (95% Cl 
-11 to 23 mg, P=0.42). At 48 hours, the placebo group had used an 
average of 15 mg more morphine than the ketorolac 10 mg group (95% Cl 
-14 to 43 mg, P=0.18) and the ketorolac 30 mg group (95% Cl -12 to 42 
mg, P=0.32), differences which were not statistically significant. 
Morphine usage was similar in the two ketorolac groups (P=0.6, and 
P=0.87 at 24 and 48 hours).
Patient pain assessment (table 9) There was no statistically 
significant difference between the drug groups for pain at rest or on 
taking a deep breath at any of the three observation times when 
measured by a VRS or VAS. Pain intensity tended to be mild at all 
times when the patient was resting, and increased with deep breathing 
in all treatment groups. On the third day, VAS for pain at rest
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24 hours 
48 hours
PLACEBO
61(3.9)
97(6.7)
KlOmg
52(6.4)
82(10)
K30mg
55(6.7)
82(10)
Table 8 Ketorolac after thoracotomy. PCA morphine consumption at 24 
and 48 hours. Mean (SE).
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hours
placebo 10 mg 30 mg
Figure 2 Mean cumulative morphine requirements 
after thoracotomy. Placebo, ketorolac 10 mg, and 
ketorolac 30 mg.
PLACEBO
PAIN AT REST 
Visual Analogue Scale 
Study day
1 26(4.5)
2 23(6)
3 19(5.4)
KlOmg
20(4.6)
29(5)
20(4.8)
K30mg
27(4.7)
19(4.8)
11(2.7)
Verbal Rating Scale 
Study day
1 1(0-3)
2 1(0-2)
3 1(0-2)
1(0-3)
1(0-2)
1(0-2)
1(0-2)
1(0-2)
1(0-2)
PAIN ON DEEP BREATHING 
Visual Analogue Scale 
Study day
1 31(4.7)
2 37(6.5)
3 26(5.6)
26(4.5)
39(5)
28(6.3)
36(5.5)
32(5)
18(4)
Verbal Rating Scale 
Study day
1 1(0-3)
2 1(0-3)
3 1(0-2)
1(0-3)
2(0-2)
1(0-3)
1(0-2)
1(0-2)
1(0-2)
Table 9 Ketorolac after thoracotomy. Pain assessments by patients at 
rest and upon taking a deep breath. Visual analogue score in mm, mean 
(SE). Verbal rating score median (range).
tended to be higher for the placebo group than ketorolac 30 mg, but 
this was not statistically significant (P=0.2, mean difference 8 mm, 
95% Cl -2 to 20).
Observer pain assessment (table 10) The observer scored pain as 
being absent or mild when the patient was at rest. There was no 
difference between the groups at any of the observation times.
Patient and observer overall score (table 11) The patients in all 
groups indicated a high degree of satisfaction with their analgesia, 
usually scoring it as good or excellent, and there was no difference 
between the treatment groups. The observer score indicated that the 
ketorolac group had better analgesia, although this only approached 
statistical significance (P=0.1, and P=0.06, Kruskal-Wallis, days 2 
and 3 respectively).
Physiotherapy assessment (table 12) There was no difference in 
the ability of the patients to comply with physiotherapy, although 
the ketorolac 30 mg group tended to have higher scores.
Sedation (table 12) There was no difference between the groups on
days 1 and 2. On day 3, 8 of 13 patients in the placebo group, 15 of 
17 in the ketorolac 10 mg group, and 21 of 22 in the ketorolac 30 mg 
group were completely awake with a sedation score of 0. The 
difference in the sedation scores of placebo and ketorolac 30 mg was 
statistically significant (P=0.01, Kruskal-Wallis). There was no 
statistically significant difference between placebo and ketorolac 10 
mg (P=0.1), or the two ketorolac groups (P=0.43).
Withdrawal rate (table 13) More patients in the ketorolac 30 mg
group completed the study than in the placebo group (P=0.005,
Fisher's exact test). There was no difference between the placebo and
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PLACEBO KlOmg K30mg
APPARENT PAIN 
Verbal Rating Scale 
Study day
1 0(0-2) 0(0-2) 0(0-1)
2 1(0-2) 1(0-2) 1(0-2)
3 0(0-2) 0(0-2) 0(0-2)
Table 10 Ketorolac after thoracotomy. Pain assessment by the 
observer. Median (range).
PLACEBO KlOmg K30mg
PATIENT 
Day 2
Poor 1/16 0/18 0/23
Fair 2/16 2/18 2/23
Good 7/16 7/18 6/23
Excellent 6/16 9/18 15/23
Day 3
Poor 0/13 0/16 0/22
Fair 0/13 0/16 2/22
Good 5/13 8/16 7/22
Excellent 8/13 8/16 13/22
OBSERVER 
Day 2
Poor 0/16 0/18 0/23
Fair 3/16 2/18 1/23
Good 8/16 4/18 9/23
Excellent 5/16 12/18 13/23
Day 3
Poor 0/13 0/16 0/22
Fair 4/13 3/16 1/22
Good 4/13 6/16 5/22
Excellent 5/13 7/16 16/22
Table 11 Ketorolac after thoracotomy. Patient and observer overall 
assessment of analgesia.
PLACEBO KlOmg K30mg
Physiotherapy 
Day 2
Poor
Fair
Good
Excellent 
Day 3
Poor
Fair
Good
Excellent
Sedation 
Day 1
Day 2
Day 3
0/16
4/16
11/16
1/16
0/13
5/13
5/13
3/13
2(0-3)
0(0-1)
0(0-2)
0/18
3/18
8/18
7/18
0/16
2/16
7/16
7/16
2(0-3)
0(0-2)
0(0-2)
0/23
2/23
11/23
10/23
0/22
0/22
10/22
12/22
1(0-3)
0(0-2)
0(0-2)
Table 12 Ketorolac after thoracotomy. Physiotherapy and sedation 
scores, median (range).
n
PLACEBO
25
KlOmg
25
K30mg
25
Day 1 4 2 2
Day 2 6 6 0
Day 3 3 2 1
Completed study 12* 15 22
Table 13 Withdrawals and completion rates in the thoracotomy study. 
Significantly less than K30mg.
ketorolac 10 mg (P=0.4), or ketorolac 10 and 30 mg (P=0.1). The 
majority of patients who withdrew were in the placebo group, and the 
most common reason for withdrawal was poor pain relief.
Of the 13 subjects in the placebo group who withdrew early, 11 
did so because of inadequate analgesia, 1 had a postoperative bleed, 
and 1 was not given a dose of study drug in error.
In the ketorolac 10 mg group, 5 withdrew because of poor 
analgesia. 1 each stopped early because of pronounced respiratory 
depression, lobar collapse of the lung requiring bronchoscopy, 
dyspepsia with respiratory depression and a low renal output, and 2 
were not given doses of study drug by mistake.
In the ketorolac 30 mg group, only 2 withdrew because of 
inadequate analgesia, and 1 patient had a postoperative bleed.
Respiratory rate and arterial blood analysis (table 14. figure 3) 
There was no difference between the three groups in respiratory rate 
or arterial blood carbon dioxide tension (PaC02, kPa)at 2, 26 and 50 
hours after the end of the operation and the beginning of the study.
Consideration of the change in PaC02 in individual patients after 
operation did, however, suggest a difference between the placebo and 
ketorolac groups (figure 3). From the two hour arterial blood sample 
to 26 hours all three groups showed a fall in PaC02« This trend 
continued in the ketorolac groups, but was not sustained in the 
placebo group so that there was no difference in PaC02 in these 
subjects at the 2 and 50 hour samples (P=0.96). Mean PaC02 was higher 
at 50 hours in the placebo group 6.14(0.42)kPa compared with the 
ketorolac 10 mg group 5.35(0.2) (P=0.1, 95%CI -0.3 to 1.9 kPa), and 
the ketorolac 30 mg group 5.5(0.26) (P=0.2, 95%CI -0.8 to 0.5kPa).
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PLACEBO KlOmg K30mg
RESPIRATORY RATE
Day 1 17(0.8) 16(1) 16(0.7)
Day 2 18(0.7) 18(0.8) 18(0.4)
Day 3 19(0.5) 20(0.9) 19(0.4)
PaC02(kPa)
Day 1 6.24(0.14) 6.43(0.16) 6.19(0.17)
Day 2 5.9(0.14) 5.78(0.15) 5.84(0.1)
Day 3 5.82(0.18) 5.28(0.16) 5.5(0.23)
Table 14 Respiratory rate and arterial blood carbon dioxide tension 
after thoracotomy. Mean (SE).
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Figure 3 Arterial blood CO2 tension after 
thoracotomy. Mean (SE).
These mean differences were not statistically significant (P=0.23, 
analysis of variance), perhaps because only 12 subjects continued in 
the placebo group to this point in the study.
Blood loss from chest drains and gastrointestinal function (table 
15) Ketorolac did not increase blood loss from wound drains. 
Gastrointestinal function, assessed by the time to return of bowel 
sounds and return to oral intake, did not differ between the groups.
Haematology and biochemistry There were no abnormal changes found 
on laboratory analysis of blood over the three study days. 
Specifically, no abnormal liver function tests were found with 
ketorolac. Changes in blood urea and electrolytes are discussed in 
chapter 6 of this thesis.
Adverse events Although five patients were withdrawn because of 
adverse events, these were not thought to be 'serious' (see chapter 
2.8).
One patient in the placebo group had a severe postoperative 
haemorrhage, and was returned to theatre where a bleeding bronchial 
artery was successfully ligated.
Three patients were withdrawn from the low dose ketorolac group. 
Two had respiratory depression, thought to be related to opioids, and 
one also had dyspepsia and a poor urine output. Both of these 
patients were given naloxone to antagonise the depressant effect of 
morphine. One subject required suction bronchoscopy to treat collapse 
of a lobe of the lung.
One patient in the ketorolac 30 mg group had a large and rapid 
blood loss from the intercostal chest drain and lobectomy and was 
withdrawn in the immediate postoperative period. The blood loss was
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BLOOD LOSS (ml) 
Day 2 
Day 3
GASTROINTESTINAL 
Bowel sounds (h) 
Oral intake (h)
PLACEBO
576(68)
308(80)
24.2(1)
27.5(1.5)
KlOmg
581(51)
364(66)
25.4(1.1)
26.9(1.5)
K30mg
653(78)
420(89)
28.7(1.8)
27(1.5)
Table 15 Blood loss from surgical drains, and time to return of 
gastrointestinal function after thoracotomy. Mean (SE).
expected as there were many pleural adhesions and it had been a 
difficult surgical dissection. Skin bleeding time was normal (200), 
and only a blood transfusion was needed.
All of these patients made a full recovery and required no 
further treatment.
Other adverse events are listed (table 16). Nausea and vomiting 
were common complaints, although relatively less so in the ketorolac 
lOmg group. The placebo group tended to have more chest infections 
postoperatively. Urinary retention and poor urine output were 
complaints associated with ketorolac. One other patient from the 
ketorolac 10 mg group had mild dyspepsia. Muscle pain after injection 
of ketorolac was not a problem.
4.1.5 Discussion This investigation did not find any clear 
benefit in administering regular intramuscular injections of 
ketorolac after thoracotomy to patients receiving morphine by patient 
controlled analgesia. Morphine use, patient and observer pain 
assessments, and compliance with physiotherapy were very similar in 
all the treatment groups (although the ketorolac groups tended to 
score slightly better). There was some evidence from the observer's 
overall score that ketorolac improved analgesia. High dose ketorolac 
was associated with less sedation on day 3 (table 12) and a higher 
study completion rate (table 13), which may be subtle indicators of 
beneficial actions of the NSAID.
There was evidence that ketorolac reduced morphine requirements 
by about 15 mg over 48 hours (table 8, figure 2), a difference which 
was not statistically significant in this study. Such a reduction in 
opioid requirement may be also considered clinically insignificant.
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PLACEBO KlOmg K30mg
Nausea, vomiting 11 4 15
Chest infection 4 1 2
Urinary retention 1 3 8
Low urine output 0 3 1
Bronchospasm 0 1 1
Dyspepsia 0 1 0
Flatulence 2 1 1
Headache 0 1 0
Table 16 Numbers of patients with adverse events after thoracotomy.
Previous studies using similar numbers of patients, found that 
administration of ketorolac (84) and indomethacin (41,38) 
significantly improved postoperative analgesia whilst reducing opioid 
requirements by around one third. Such an effect was not found in 
this study, and it may be reasonable to make comparisons with these 
earlier investigations to discern why there should be such different 
results from the present study. It should be noted that not all 
studies have found that NSAIDs improve analgesia or reduce opioid 
requirements (49,50).
Gillies and others (84) studied 61 patients after upper abdominal 
surgery who were given continuous intramuscular infusions of saline, 
ketorolac 1.5 mg/hr, or ketorolac 3 mg/hr, for 24 hours. In a similar 
fashion to this study, morphine requirements were measured using a 
patient-controlled analgesia system. Patients who were given 
ketorolac required on average 25 mg less morphine in twenty-four 
hours, had better pain relief, and less postoperative increase in 
arterial carbon dioxide tensions than controls. Doses of ketorolac 
were slightly lower than in this study at 36 mg (low dose) or 72 mg 
(high dose) over 24 hours. It may be that continuous infusions of 
ketorolac are more effective than intermittent injections, and there 
is some evidence to that effect (215,216). Ketorolac has a relatively 
short half-life (65,66,67) and six-hourly intramuscular 
administration may not be frequent enough; perhaps a continuous low 
dose infusion would have been better. Also the severity of pain 
experienced by the patients may have differed between the studies; 
upper abdominal surgery may be more painful than thoracotomy allowing 
patients to derive more benefit from addition of an NSAID. Indeed the 
pain scores reported by Gillies and others were appreciably higher 
than those recorded after thoracotomy in this study. Also,
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intercostal nerve blockade was performed in this study using 
bupivacaine, a long acting local anaesthetic, which may also reduce 
postoperative pain. There is evidence that patients are better able 
to compare between analgesics in the presence of severe pain (83). An 
additional factor is that the patients enrolled in this study were 
older than in Gillies and others, and age is an important determinant 
of analgesic requirement (184).
In comparison with the work of Gillies and others (84), the 
identifiable reasons for the different result in this study are that 
ketorolac was given intermittently (not continuously), pain severity 
may have been less (operative site, local anaesthetic block), and 
analgesic requirements may have differed in the more elderly patients 
in this study.
Pavy and others (41) studied the effect of indomethacin on pain 
relief after thoracotomy, confirming the beneficial results reported 
by Reasbeck and colleagues after abdominal surgery (38). 60 patients 
were given either indomethacin (200mg at the end of surgery then 
lOOmg twice daily) or placebo suppositories. Postoperatively patients 
were given papaveretum by continuous infusion which was adjusted by 
the nursing staff to give adequate pain relief. Indomethacin resulted 
in improved pain relief and a significant reduction of papaveretum 
requirements (about 40 mg over 48 hours). In comparison with the 
study described in this thesis, the obvious differences are that Pavy 
and colleagues used a different NSAID by suppository, with continuous 
infusions of opioid adjusted to analgesic effect by staff, and did 
not use intercostal nerve blockade. Indomethacin could be more 
effective than ketorolac, but there have been no comparative studies. 
Suppository may deliver the drug at more constant rates providing 
more stable blood concentrations than intermittent injections, like
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the intramuscular infusions of Gillies and others (84). PCA should be 
more sensitive to the needs of the patient than continuous infusions 
altered by nursing staff. The pain scores reported by Pavy and 
colleagues for their control group were again appreciably higher than 
in the study presented in this thesis (41). It is possible that pain 
relief given by continuous infusion of papaveretum gave poorer 
analgesia than morphine by PCA, and paradoxically allowed the 
benefits of indomethacin to be more obvious. It should be noted that 
Pavy and others did not use intercostal nerve block during surgery, 
which would be expected to increase pain severity, again perhaps 
allowing the benefit of NSAID administration to be more obvious.
In this study, there was some indication that ketorolac 
administration was associated with lower PaC02 values on the second 
postoperative day (figure 3), although statistical significance was 
not reached. This may be evidence of continuing respiratory 
depression in the patients in the placebo group, who were also more 
sedated at this time (table 12). The high PaCC>2 values two hours 
after operation (table 14) may result from the residual effects of 
anaesthesia and it could have been expected that tensions would fall 
thereafter towards preoperative values. Unfortunately the present 
study did not investigate this fully, as arterial blood was not 
sampled in the preoperative period, but earlier studies have shown 
that ketorolac does reduce postoperative changes in PaC02 (84), and 
indomethacin minimises postoperative respiratory depression (38).
This may be an important beneficial effect of ketorolac, even in the 
late postoperative period when respiratory side-effects are known 
still to occur (33) and when oxygen supplementation is normally 
stopped. This effect of ketorolac administration may be worthy of 
further study.
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The adverse events seen were unlikely to result from ketorolac 
administration. One individual did have a brisk blood loss after 
ketorolac 30 mg, but the dissection had been difficult and platelet 
function as assessed clinically by the skin bleeding time was normal. 
As in the cholecystectomy study (Chapter 3.2), gastrointestinal 
problems with ketorolac were uncommon. Two patients in the low dose 
ketorolac group had dyspepsia, but none complained of this with the 
higher dose of the NSAID. Liver function was not impaired by 
ketorolac. Urinary retention and low urine output (which were not 
clearly distinguished in this investigation) may have been associated 
with ketorolac administration.
4.1.6 Conclusion There was no clear benefit in giving ketorolac 
intramuscularly to patients after thoracotomy who had had intercostal 
nerve block and were receiving morphine by PCA. In comparison with 
previous studies, the absence of any benefit of ketorolac could have 
resulted from the intermittent method of administration, the low pain 
state associated with intercostal nerve block and the use of PCA, as 
well as the age of the patients.
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CHAPTER 5
THE EFFECT OF KETOROLAC AND DICLOFENAC ON PLATELET FUNCTION
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5.1 Introduction
If the use of NSAIDs as postoperative analgesia becomes accepted 
practice, ketorolac may be used during and after surgery, just as 
diclofenac has become popular (45,47). There is some concern over the 
perioperative use of NSAIDs as they prevent thromboxane A 2 (TXA2 ) 
production by inhibition of cyclo-oxygenase (13). TxA2 and cyclic 
endoperoxides are important mediators of platelet aggregation and 
vasoconstriction, processes involved in the primary haemostatic 
response to vessel injury (91). Specific receptors for TxA2 and 
cyclic endoperoxides have been isolated in human platelets (92). The 
possibility exists therefore, that NSAID administration during 
surgery could affect platelet function, impair haemostasis, and 
increase blood loss. Indeed concern has been expressed about the use 
of diclofenac during major surgery, until detailed studies of the 
platelet effects have been performed (48).
NSAIDs and aspirin, which has a similar inhibitory effect on 
cyclo-oxygenase, inhibit platelet aggregation and prolong bleeding 
time in volunteers (94,95,100). There is insufficient information on 
the perioperative situation where the haemostatic response may be 
altered by the stress of surgery, although aspirin is well recognised 
to be a cause of postoperative bleeding (97,98).
Patients undergoing surgery may be given heparin or dextran as 
prophylaxis against deep venous thrombosis (105,106), and these could 
interact with NSAIDs. The effect of ketorolac with heparin has been 
studied in volunteers (103), but there is little information on the 
effect in patients. It is known that the combination of aspirin and 
heparin, an effective prophylaxis against deep venous thrombosis 
(217), can be associated with severe bleeding problems (218).
Dextrans are used intravenously during surgery for volume expansion
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as well as prophylaxis against venous thrombosis, and have some anti­
platelet effects. There have been no investigations of the potential 
interaction between NSAIDs and dextran on haemostasis.
The methods described in Chapter 2.4 were used to investigate 
the effect of ketorolac and diclofenac on skin bleeding time, whole 
blood platelet aggregation and operative blood loss, and also to 
assess combinations of ketorolac and dextran-70.
5.2 The effect of ketorolac 30 mg on platelet function and blood loss 
during cholecystectomy
5.2.1 Introduction The effect of ketorolac on platelet function 
was observed in patients enrolled into the cholecystectomy study, 
described in Chapter 3.2 of this thesis. Operative blood loss (100 
patients), skin bleeding time (20 patients), and whole blood platelet 
aggregation (10 patients) were observed in a double-blind randomized 
study of ketorolac 30 mg and morphine 10 mg. All patients were given 
subcutaneous heparin (5000 iu) one hour before surgery.
5.2.2 Methods The study protocol for the cholecystectomy study 
is described in Chapter 3.2.2. Patients were given either ketorolac 
30 mg or morphine 10 mg by intramuscular injection after induction of 
anaesthesia. In all 100 patients in the cholecystectomy study 
operative blood loss was estimated by weighing swabs in theatre. 
Within the randomization schedule, in 10 subjects from each of the 
ketorolac and morphine groups the skin bleeding time was recorded 
before surgery and one hour after the first dose of study medication. 
In 10 of these 20 subjects in vitro platelet aggregation studies were 
also performed at the same time. None of the 20 subjects was a
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cigarette smoker. In this way, changes in skin bleeding time and 
platelet aggregation were observed after ketorolac and morphine. The 
methods used for skin bleeding time and in vitro platelet aggregation 
studies are described in full in Chapter 2.4. In this study, 
spontaneous, collagen induced, and arachodonic acid induced in vitro 
platelet aggregation was examined.
Statistical analysis Between group comparisons (operative blood 
loss) were made using unpaired t-tests, and changes within individual 
patients after drug administration (skin bleeding time, platelet 
aggregation) were analysed using paired t-tests.
5.2.3 Results
Patient details These have previously been summarized in this 
thesis (table 2).
Operative blood loss (Figure 4) There was no statistical 
difference in the blood loss of the two groups (P=0.71); the mean 
loss of the ketorolac group was 218 ml (SE 19, range 20-580 ml), and 
the morphine group 231 ml (SE 30, range 25-950 ml).
Skin bleeding time (Table 17) This was significantly prolonged 
by ketorolac from a mean of 223 to 297 s (P=0.007, 95% Cl 26 to 123 
s). After ketorolac the longest bleeding time was 369 s, an increase 
of 214 over the control value, but still within the upper limit of 
normal of 600 s. The morphine group showed no change in bleeding time 
(P=0.33, 95% Cl -14 to 5 s).
Platelet aggregation (Table 17. figures 5. 6 and 7) Spontaneous 
platelet aggregation was unchanged after ketorolac. Collagen and 
arachidonic acid induced aggregation were reduced after ketorolac, 
but statistical significance was approached only for collagen induced 
aggregation, perhaps due to the small number of patients studied.
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Figure A Operative blood loss during 
cholecystectomy.
Before After P
Skin bleeding time (s)
ketorolac
morphine
223(16)
242(14)
297(14)
237(14)
0.007
0.33
Platelet aggregation
Spontaneous 
5 min: 
ketorolac 
morphine
59 (4) 
57 (5)
62 (6) 
57 (7)
0.13
0.79
10 min:
ketorolac
morphine
44 (6) 
42 (3)
45 (4) 
44 (5)
0.9
0.51
Collagen 
1 min: 
ketorolac 
morphine
26 (7) 
18 (5)
56 (16) 
15 (3)
0.2
0.52
3 min:
ketorolac
morphine
14 (2) 
11 (3)
37 (13) 
8 (2)
0.1
0.26
5 min:
ketorolac
morphine
15 (2) 
12 (2)
35 (11) 
9 (2)
0.16
0.48
Arachidonic acid 
1 min: 
ketorolac 
morphine
39 (14) 
23 (11)
59 (9) 
13 (4)
0.45
0.24
3 min:
ketorolac
morphine
27 (10) 
16 (7)
49 (7) 
9 (1)
0.25
0.38
5 min:
ketorolac
morphine
24 (6) 
13 (2)
49 (7) 
10 (2)
0.26
0.11
Table 17 The effect of ketorolac 30 mg on skin bleeding time and 
whole blood platelet aggregation. Values before and one hour after 
intramuscular injection of ketorolac or morphine. Whole blood 
platelet aggregation is expressed by the percentage of platelets 
present in the sample at each time (baseline count = 100%). Mean 
(SE), P: paired t-test.
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Figure 5 Spontaneous platelet aggregation (ketorolac).
The percentage of unaggregated platelets in the sample
is plotted against time. Mean (SE).
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Figure 6 Collagen induced platelet aggregation
(ketorolac). Mean (SE).
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Figure 7 Arachidonic acid induced platelet aggregation
(ketorolac). Mean (SE).
Collagen and arachidonic acid aggregation depend on thromboxane 
production, spontaneous aggregation does not. There was no change in 
platelet aggregation in the morphine control group under any 
condition.
5.2.4 Discussion A  single intramuscular dose of ketorolac 30 mg 
given at induction of anaesthesia did not increase the operative 
blood loss of cholecystectomy, even in the presence of heparin. 
However, platelet function was affected, and ketorolac prolonged skin 
bleeding time and tended to inhibit platelet aggregation as observed 
in volunteer studies (102,103). The effect was similar to that of a 
single dose of aspirin, and may be clinically insignificant because 
none of the bleeding times after ketorolac were abnormal (94).
5.3 The effect of diclofenac 75 mg on platelet function during 
thoracotomy
5.3.1 Introduction The effect on platelet function and 
haemostasis of diclofenac 75 mg intramuscularly given at induction of 
anaesthesia was investigated in patients having thoracotomy for lung 
resection. The patients were also given subcutaneous heparin before 
surgery.
5.3.2 Methods Twenty patients undergoing thoracotomy were 
studied, aged 27 to 79 years. The anaesthetic technique was as 
described in this thesis for the thoracotomy study using ketorolac 
(Chapter 4). Subcutaneous heparin (2500 iu subcutaneously, one hour 
preoperatively) was given as prophylaxis against deep venous 
thrombosis. All patients had intercostal nerve blocks before surgery
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(bupivacaine 0.5%). The subjects were randomly allocated so that ten 
of them were given 75 mg diclofenac intramuscularly at induction of 
anaesthesia. The clinician administering the injection was not 
otherwise involved in the study.
Skin bleeding times (all subjects) and platelet function tests 
(ten subjects) were done on the day before surgery, and repeated one 
hour after induction of anaesthesia. Surgical blood loss was 
estimated by the weighing of swabs at operation and collection of 
suction blood. In five subjects in each group, whole blood platelet 
aggregation was studied in vitro as described in Chapter 2.4. In this 
study, because of cost, only collagen (2 fig ml“l, Semmelweiss) was 
used as an aggregating agent for the in vitro platelet studies.
20 patients entered and completed the trial. No adverse events 
were encountered.
Statistical analysis As in the previous study, unpaired and 
paired t-tests were used to analyse blood loss and changes in skin 
bleeding time and platelet aggregation.
5.3.3 Results
Patient details and blood loss (table 18) The diclofenac and 
control groups were similar in age, height, weight, smoking history, 
and sex distribution. Surgical procedures performed were lobectomy (5 
diclofenac; 4 control), pneumonectomy (2 diclofenac; 2 control), open 
lung biopsy (2 each group), pleurectomy (1 diclofenac), and 
thoracotomy with no resection (2 control). Blood loss did not differ 
between the groups (P=0.80), although there was a wide range within 
each group (diclofenac 20 to 1200 ml; control 20 to 1700ml).
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Diclofenac Control P
Age (years) 
Height (cm) 
Weight (kg) 
Smoker (Y/N)
Sex (M/F)
Blood loss (ml)
61.2 (13.9)
163.1(4.4)
62.5 (10.1)
4/6
4/6
352 (125)
61.1 (13)
164.9(5.4)
67.7 (9.8)
2/8
4/6
300 (165) 0.8
Table 18 Diclofenac and platelet function. Patient details (mean, SD) 
and blood loss (mean, SE). P: unpaired t-test.
Skin bleeding time (table 19) This was significantly prolonged 
one hour after diclofenac 75 mg im from a mean of 250 s to 330 s 
(P=0.0001, 95%CI 47 to 115 s). There was no change in the control 
group (P=0.66, 95%CI -24 to 16). After diclofenac the range of 
bleeding times was from 247 to 480 s. The longest prolongation of 
bleeding time in a subject was from 350 s before diclofenac to 480 s 
after, but this is still within the normal upper limit of 600 s.
Whole blood platelet aggregation (table 19. figures 8 and 9) 
Diclofenac significantly reduced collagen induced in vitro platelet 
aggregation at the three and five minute sample times, but not at one 
minute. At five minutes, the 95% Cl for the reduction in platelet 
aggregation with diclofenac was from -35.5 to -1.7%. The control 
group showed a tendency towards reduced aggregation one hour after 
induction of anaesthesia, but this was not statistically significant 
(at five minutes P=0.09, 95% Cl -13 to 1.4%).
5.3.4 Discussion This study has demonstrated that one hour after 
an intramuscular dose of diclofenac 75 mg skin bleeding time is 
prolonged and whole blood platelet aggregation is inhibited. As 
already noted, skin bleeding time is a useful clinical test of 
platelet function, and collagen induced aggregation depends largely 
on thromboxane production by platelet cyclo-oxygenase. In the 
relatively small number of patients studied, blood loss was not 
increased by diclofenac.
Previous work found no change in skin bleeding time in patients 
twenty four hours after an intramuscular dose of diclofenac 33.6 mg 
followed by an intravenous infusion of 6.7mg/hr (40). This was a 
surprising observation in view of the known effect of cyclo-oxygenase 
inhibitors on thromboxane production. The present study has
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Before After P
Skin bleeding time (s)
Diclofenac 250(16.9) 330(19.7) 0.0001
Control 226(18.7) 222(15.5) 0.66
Diclofenac platelet aggregation
1 minute 34(11) 48(14) 0.077
3 minutes 17(6) 26(6) 0.024
5 minutes 17(5) 36(9) 0.038
Control platelet aggregation
1 minute 30(16) 40(11) 0.38
3 minutes 14(3) 18(4.4) 0.1
5 minutes 16(4) 22(4) 0.1
Table 19 The effect of diclofenac 75 mg on skin bleeding time and 
collagen induced whole blood platelet aggregation. Bleeding times are 
shown for each group of ten subjects before and one hour after 
diclofenac injection. For platelet aggregation the values shown are 
the percentage of free platelets present at each time in the presence 
of a collagen aggregator. Mean (SE). P: paired t-test.
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Figure 8 Collagen induced platelet aggregation
(diclofenac). Mean (SE).
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Figure 9 Collagen induced platelet aggregation
(control). Mean (SE).
demonstrated that the clinically recommended adult diclofenac 
intramuscular dose, 75mg, affects skin bleeding time within one hour 
of administration in patients having surgery.
The mean increase in skin bleeding time seen with diclofenac 75 
mg was 80 seconds (95%CI 47 to 115 seconds, table 19). This is 
comparable with the change of 74 seconds (95% Cl 26 to 123 seconds, 
table 17) produced by ketorolac 30 mg, reported in section 2 of this 
chapter, and is similar to the effect of aspirin (94). Whole blood 
platelet aggregation was inhibited similarly by ketorolac and 
diclofenac. As with ketorolac, skin bleeding time was prolonged by 
diclofenac, but not above the upper limit of 600 seconds. Indeed the 
longest bleeding time after diclofenac was only 480 seconds. 
Therefore, although ketorolac and diclofenac affect platelets, they 
may not produce an abnormal haemostatic state in previously normal 
individuals. However, it has been shown that certain members of the 
population are more sensitive to the haemostatic effects of aspirin 
than others (201,219) and so some patients could have a greater 
effect from ketorolac or diclofenac than reported here.
In contrast to the ketorolac study, this investigation was not 
large enough to investigate properly the effect of diclofenac 75 mg 
on operative blood loss after thoracotomy. Previous studies have 
found that preoperative administration of lower doses of diclofenac 
do not increase blood loss after gynaecological laparotomy (33.6 mg 
intravenously; 40) or transurethral prostatectomy (50 mg orally; 
220). Experience with other NSAIDs suggests that the dose used is 
important in determining whether blood loss is increased or not. For 
example, in gynaecological laparotomy preoperative intravenous 
indomethacin 0.8 mg/kg increased intraoperative blood loss (39), but 
25 mg did not (40). The clinically used intramuscular dose of
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diclofenac is 75 mg, and further studies are required to ascertain 
whether the platelet dysfunction produced by this is associated with 
increased blood loss.
There was a tendency towards reduced platelet aggregation in the 
control group which was statistically insignificant (table 19) but as 
it could reflect the effects of anaesthesia and surgery on platelet 
function it may merit further study.
5.3.5 Conclusion Ketorolac 30 mg and diclofenac 75 mg when given 
intramuscularly impair platelet function within one hour. The 
magnitude of this effect is similar to a single dose of aspirin. This 
effect should be considered if blood loss seems excessive when they 
have been given intraoperatively, although blood loss was not 
increased by ketorolac after cholecystectomy, or by diclofenac after
thoracotomy, even in the presence of heparin. It may be prudent to
avoid the use of ketorolac, diclofenac or another NSAID in the 
presence of other defects of haemostasis or coagulation. Indeed the 
administration of an NSAID could reveal a subclinical haemostatic 
problem, and if this was suspected the skin bleeding time would be a
useful clinical test to perform (219).
5.4 Haemostatic effects of ketorolac with and without concomitant 
dextran in normal volunteers
5.4.1 Introduction Ketorolac is therefore a potent inhibitor of 
platelet aggregation and haemostasis, and is active within one hour 
of intramuscular administration. The possible interaction between 
dextran, given for prophylaxis of venous thrombosis especially during 
hip surgery (105), and NSAID administration has not been
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investigated. Other NSAIDs have been recommended for the relief of 
pain after hip operations (46,47). As ketorolac will be used during, 
as well as after, surgery, it would seem important to demonstrate 
that there is no adverse haemostatic interaction with dextran.
As discussed in Chapter 2.4.1, the precise mode of action of 
dextran is unclear, but may involve a beneficial effect due to 
haemodilution and improved blood flow, as well as haemostatic effects 
which include anti-platelet effects, a fall in factor VIII and 
increased tissue plasminogen activity (198). Dextran increases skin 
bleeding time by reducing platelet adhesiveness, but is not thought 
to have any effect on thromboxane synthesis. A  disadvantage of the 
use of dextran is the risk of anaphylactoid reaction, but this can be 
significantly reduced by pretreatment with the low molecular weight 
hapten dextran (dextran-1) (198), although this is not freely 
available in this country. Of the various molecular weights of 
dextran available, dextran-70 is used most often during surgery for 
volume expansion and prophylaxis of venous thrombosis, and this 
preparation was used in this study (Macrodex, Pharmacia).
The object of this volunteer study was to determine if there was 
any risk of impairing haemostasis by giving ketorolac with dextran- 
70. Platelet function was investigated by measuring skin bleeding 
time, whole blood platelet aggregation, and thromboxane production.
To investigate possible effects of dextran on coagulation and 
fibrinolysis, von Willebrand Factor antigen (vWF:AG), factor VIII 
coagulant activity (FVIIIc), and tissue plasminogen activator antigen 
(tPA antigen) were measured (Chapter 2.4).
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5.4.2 Methods
Volunteers Twelve healthy male volunteers were enrolled with no 
history of atopy, asthma, bleeding disorders, or previous exposure to 
dextran. If a subject withdrew for any reason then provision was made 
for a replacement volunteer to be recruited.
Subjects avoided aspirin intake for at least two weeks before 
and also during the study. Similarly caffeine ingestion and cigarette 
smoking were forbidden for a day before each study period.
Study design A  double-blind, randomized, crossover study of 
healthy male volunteers. On four separate study days the volunteer 
was given one of the following combinations:
ketorolac placebo/dextran placebo 
ketorolac active/dextran placebo 
ketorolac placebo/dextran active 
ketorolac active/dextran active
At the end of the study period each volunteer had been given 
each of the four combinations. Allocation of the volunteers to 
treatment order was randomized by a four by four latin square design.
Ketorolac was supplied as 30 mg in 1ml amber coloured ampoules, 
and dextran as dextran 70 in sterile 5% dextrose solution. Matching 
placebos were supplied so that all four combinations were identical 
in appearance.
Drug administration On each study day an intravenous infusion 
was commenced at 10 am containing 500 ml of dextran-70 or dextrose 5% 
placebo. At 2 pm the intramuscular injection of ketorolac 30mg or 
placebo was given to the deltoid muscle using a 23G needle. One hour 
later skin bleeding time was performed and blood taken for analysis.
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The peak effect of dextran is thought to occur 4 to 6 hours 
after administration, and peak blood levels of ketorolac are seen one 
hour after intramuscular injection. Observations and measurements 
were therefore made when both dextran and ketorolac should have been 
active.
Because anaphylactoid reactions to intravenous dextrans occur 
once in 400 exposures, and this may be reduced by pretreatment with 
dextran-1 (hapten dextran, Pharmacia), each subject was given 
dextran-1 intravenously at the beginning of every study day before 
the dextran-70/placebo infusion.
Platelet function, skin bleeding time, and fibrinolysis On the 
first and last study days control tests were performed before any 
drugs were given to check that there were no baseline changes. On 
each day testing was repeated at the end of the study period one hour 
after the intramuscular injection (3pm).
Investigations The methods and techniques used in this study are 
described in detail in Chapter 2.4. Platelet function was assessed by 
skin bleeding time and in vitro platelet aggregation (using collagen 
and arachidonic acid aggregators). Venous blood thromboxane B 2 (TxB£) 
generation was also measured. To investigate dextran effects on 
coagulation and fibrinolysis, von Willebrand Factor antigen (vWF:Ag), 
factor VIII coagulant activity (FVIIIc), and tissue plasminogen 
activator antigen (tPA antigen) were measured.
Injection site abnormalities At the end of each study day the 
site of the intramuscular injection was examined by the observer for 
evidence of bruising, and this was recorded as none, mild, moderate, 
or severe. The subject was asked to comment whether the intramuscular 
injection had produced no, mild, moderate, or severe pain.
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Adverse events All adverse events were recorded. During the 
intravenous infusion arterial blood pressure was monitored because of 
the incidence of anaphylactoid reactions to dextran, and the study 
was performed in a ward setting where resuscitation drugs and 
equipment were readily available.
Statistical analysis The variables used were skin bleeding 
times, whole blood platelet aggregation, venous blood TxB£, vWF:Ag, 
FVIIIc, and tPA antigen. Because of the skewed nature of venous blood 
TxB2 values the analysis was performed on logged data, and results 
given in the tables as mean (range).
To examine whether the baseline variables changed during the 
course of the study control measurements were performed on days 1 and 
4 before drugs were given, and were compared using a paired t-test.
Analysis of values after drug treatment was by analysis of 
variance which fitted subjects, period (order of drug combination 
administration), and treatment effects. Only the treatment effect was 
found to be significant so the others were omitted from further 
analysis. The treatment effect was then divided into a 'ketorolac' 
effect, a 'dextran' effect, and their interaction.
5.4.3 Results
Volunteers All subjects were healthy males, mean age 31(9) year, 
mean weight 76.6 (8.8) kg, mean height 179 (6.1) cm. Eleven 
volunteers completed four study days. One subject completed only two 
days and was withdrawn because of an allergic reaction to dextran, 
and unfortunately his replacement also withdrew after completing two 
study days when he was involved in a road traffic accident. These two
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subjects, who attended for prestudy screening and two study days each 
(covering all four treatment combinations), were included in the 
analysis.
Baseline tests On day 1, the baseline mean skin bleeding time 
was 340 (29)s, range 169-538s. On day 4, the baseline bleeding time 
was 376 (32)s, range 285-565s. This change was not statistically 
significant (P=0.3).
Skin bleeding time (table 20) The mean increase in skin 
bleeding time with ketorolac was 69s, although this was not 
statistically significant (P=0.19, 95% Cl -37 to 175s). Dextran 
produced a mean increase of 50s, but again this was not statistically 
significant (P=0.33, 95% Cl -52 to 151 s). There was no evidence of 
an interaction between ketorolac and dextran (P=0.90), although 
bleeding times tended to be higher when both active treatments had 
been given.
Platelet functions tests (table 20) In the presence of a 
collagen aggregator, ketorolac significantly increased the number of 
unaggregated platelets by a mean of 23% of the baseline count over 
five minutes (P=0.0001, 95% Cl 15 to 31%). Dextran had no effect 
(P=0.53) and there was no interaction between ketorolac and dextran 
(P=0.38).
With arachidonic acid, ketorolac again had a significant effect, 
increasing the number of unaggregated platelets present at five 
minutes by 39% of the baseline count (P=0.0001, 95% Cl 30 to 48%). 
Dextran had little effect (P=0.25), and there was no interaction 
between ketorolac and dextran (P=0.24).
Whole blood thromboxane B? (TxB?) generation (table 21) TxB2 
concentrations were lower by a factor of 39.8 after ketorolac 
(P=0.0001, 95% Cl 28.5 to 55.5). Dextran had no effect (P=0.90).
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Skin bleeding ti
Ketorolac
placebo
Ketorolac
active
(s)
Dextran placebo 
404(47)
479(54)
Dextran active 
460(47)
522(54)
Collagen induced platelet aggregation
Dextran placebo Dextran active
Ketorolac 13(4) 12(4)
placebo
Ketorolac 32(4) 38(5)
active
Arachidonic acid induced platelet aggregation
Dextran placebo Dextran active
Ketorolac 12(4) 12(4)
placebo
Ketorolac 46(4) 56(5)
active
Table 20 The effect of ketorolac and dextran on skin bleeding time 
and collagen and arachidonic acid induced whole blood platelet 
aggregation (percentage free platelets at five minutes). Mean (SE)
Dextran placebo
Ketorolac 236.4(40-817.5)
placebo
Ketorolac 8.3(3-28.8)
active
Dextran active 
323.5(87.2-762.5)
5.8(3-16.4)
Table 21 The effect of ketorolac and dextran on venous blood 
thromboxane B2 . ng/ml, mean (range).
There was an interaction between ketorolac and dextran which was 
statistically significant (P=0.04), but this was much smaller than 
the effect of ketorolac alone.
Von Willebrand Factor antigen (vWF:Ag)(table 22) Dextran 
produced a statistically insignificant reduction in vWF:Ag of 12.3 
iu/dlitre (P=0.15, 95%CI -29.6 to 4.9 iu/dlitre). There was no 
evidence of an effect of ketorolac (P=0.99), or an interaction 
(P=0.70).
Factor VIII coagulant activity (FVIIIc) (table 22) Dextran 
reduced FVIIIc by a mean of 13 iu/dlitre (P=0.04, 95% Cl -25 to -1 
iu/dl). Ketorolac had no effect (P=0.33), and there was no 
interaction between the two drugs (P=0.17).
Tissue plasminogen activator antigen (tPA antigen) (table 22)
There was no effect of ketorolac (P=0.32), dextran (P=0.81), or any 
interaction (P=0.73).
Injection site abnormalities and pain No bruising or prolonged 
tenderness occurred at the intramuscular injection site, but four 
subjects experienced mild or moderate pain when ketorolac was 
injected, whereas pain did not occur upon placebo injection.
Adverse events One volunteer was withdrawn after an adverse
reaction to intravenous dextran, consisting of pruritis, mild
vasodilatation and hypotension. Dextran administration was stopped, 
no specific treatment was required, and the subject recovered 
uneventfully. There were no other adverse events, and no clinically 
significant changes on biochemical and haematological analysis of 
blood.
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vWF:Ag (iu/dlitre) Dextran placebo
Ketorolac
placebo
Ketorolac
active
91(8)
95(9)
FVIIIc (iu/dlitre) Dextran placebo
Ketorolac
placebo
Ketorolac
active
tPA (ng/ml)
Ketorolac
placebo
Ketorolac
active
70(6)
72(7)
Dextran placebo 
12.3(0.8)
11.7(0.9)
Dextran active 
82(8)
79(9)
Dextran active 
65(6)
51(7)
Dextran active 
12.4(0.8)
11.2(0.9)
Table 22 The effect of ketorolac and dextran on von Willebrand factor 
antigen, factor VIII coagulant activity, and tissue plasminogen 
activator. Mean (SE).
5.4.4 Discussion There was an increase in skin bleeding time of 
69 s after ketorolac, but this was not statistically significant.
This result is similar to previous work in volunteers (103) and 
patients (Chapter 5.2). The potency of ketorolac as a cyclo-oxygenase 
inhibitor was confirmed by the marked reduction in thromboxane 
synthesis (revealed by venous blood TxB£ concentration). Blood TxB2 
is used to investigate the rate of production of thromboxane A 2 which 
is metabolized rapidly in the circulation (4,8). There was evidence 
of a small but statistically significant interaction between 
ketorolac and dextran on TxB2 concentration. There was a trend for 
skin bleeding times to be higher when ketorolac was given in 
combination with dextran, which, although statistically 
insignificant, may have reflected the interaction seen with TxB2 » 
There was little change in coagulation factors, but dextran reduced 
FVIIIc, and this could have resulted from haemodilution. Dextran may 
enhance fibrinolytic activity by increasing tissue plasminogen 
activity (198), but using a modern Elisa technique for tPa antigen we 
could find no evidence of this. There was also no evidence of any 
effect of dextran-70 on the endothelium from the measurements of
vWF:A g .
Four subjects experienced' mild or moderate pain upon ketorolac 
injection, but this did not result in prolonged discomfort suggesting 
that muscle damage is not a problem with this drug (64).
5.4.5 Conclusion Ketorolac decreased platelet function probably 
by inhibiting thromboxane generation, while dextran by itself had no 
effect. The combination of ketorolac and dextran resulted in a small 
but significant interaction with respect to TXB2 ; there was no 
significant effect on skin bleeding time or platelet aggregation. The
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clinical significance of the combination effect on TxB2 is unclear as 
it was much smaller than that of ketorolac alone. FVIII coagulant 
activity was decreased by dextran.
Although we have seen no gross abnormality of haemostasis in 
this volunteer study, simultaneous use of ketorolac and dextran-70 
should be carefully monitored for any adverse effect.
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CHAPTER 6
THE EFFECT OF KETOROLAC AND DICLOFENAC ON RENAL FUNCTION
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6.1 Introduction
Renal prostaglandins have many physiological roles (116) and 
NSAIDs can adversely affect renal function in certain circumstances 
(61,90,108,110,111,112). Because the use of NSAIDs after surgery is 
becoming common, it would seem important to assess this problem. This 
thesis examines the clinical relevance of inhibition of renal 
prostaglandin production in surgical patients.
It would have been desirable to study in detail the renal effects 
of the new agent ketorolac, but this was not possible because the 
manufacturers were unwilling to release supplies of this drug for 
such a study. The renal effect of ketorolac was therefore assessed by 
serial blood urea, creatinine, and electrolyte concentrations from 
patients in the cholecystectomy and thoracotomy studies previously 
described in this thesis (Chapters 3,4).
A detailed study was performed concerning the effect of giving 
diclofenac during and after major surgery. Fluid and electrolyte 
balance, renal function, and renal production of prostacyclin were 
observed.
All the methods used in these studies to investigate renal 
function are described in Chapter 2.5.
6.2 The effect of ketorolac on renal function
6.2.1 Methods In the cholecystectomy and thoracotomy studies 
described earlier in this thesis (Chapters 3,4) renal function was 
assessed by biochemical analysis of venous blood during the period of 
study.
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In the cholecystectomy study (Chapter 3.2), blood was sampled 
after 24 hours so that 50 patients given ketorolac could be compared 
with 50 controls. In the thoracotomy study (Chapter 4), repeat 
sampling was performed at the end of the study period so that the 
effect of ketorolac at low and high doses over 48 hours could be 
examined, and compared with a placebo group.
During these studies intravenous fluid administration was 
standardized as far as possible. After cholecystectomy, patients were 
given six hourly dextrose 5% 500 ml alternating with normal saline 
500 ml. The results of this study have indicated that there was a 
tendency for the ketorolac group to require fluids for a shorter time 
(table 6). In the thoracotomy study, intravenous Hartmann's solution 
(sodium 131, potassium 5, calcium 2, chloride 111, and lactate 29 
mmol/litre approximately) was alternated with dextrose 5% at the rate 
of 500 ml six hourly. Other fluids, including blood and colloids, 
were also administered when clinically indicated.
Statistical analysis Plasma urea, creatinine, and electrolyte 
concentration were measured before and after surgery. Changes within 
patients were examined using paired t-tests. In addition, the number 
of patients who had biochemical results outwith the laboratory range 
of normal during the period of study are listed for each drug 
treatment (normal values for the laboratory are given in Chapter 
2.5.1).
6.2.2 Results
Ketorolac after cholecystectomy (tables 23.24) No clinical 
problems were encountered with renal function during the 
cholecystectomy study. Biochemical abnormalities were mild and did 
not differ between the ketorolac and morphine groups (table 23). No
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Potassium 
>4.7 mmol/litre
Sodium
<132 mmol/litre 
Urea
>6.6 mmol/litre
Creatinine 
>150 /imol/litre
Ketorolac
0
2
4
0
Morphine
1
3
4 
0
Table 23 Ketorolac and renal function. The number of patients with 
abnormal clinical chemistry results after cholecystectomy.
Preoperative 24 h P
Ketorolac
Sodium 140(0.3) 138(0.4) 0.002
Potassium 3.9(0.1) 3.8(0.1) 0.25
Urea 4.8(0.2) 4.1(0.2) 0.003
Creatinine 82(3) 85(3) 0.5
Morphine
Sodium 140(0.2) 136(0.4) 0.000
Potassium 4.1(0.1) 3.9(0.1) 0.02
Urea 5(0.2) 3.6(0.3) 0.000
Creatinine 85(2) 79(3) 0.02
Table 24 The effect of ketorolac on renal function after 
cholecystectomy. Plasma urea, creatinine, and electrolytes before, 
and after 24 hours. Mean (SE), P: paired t-test. Sodium, potassium, 
urea in mmol/litre and creatinine in ^mol/litre.
patient developed severe hyperkalaemia, the highest postoperative 
potassium concentrations being 4.5 mmol/1 and 4.9 mmol/1 in the 
ketorolac and morphine groups respectively.
The two groups differed in the changes seen within individual 
patients in plasma urea, creatinine and electrolytes over the 24 hour 
study period (table 24). In the morphine control group there was a 
significant fall in urea, creatinine, sodium, and potassium one day 
after operation from baseline values. In the ketorolac group only 
urea and sodium concentrations fell (but to a lesser extent) and 
there was no fall in plasma potassium or creatinine.
Ketorolac after thoracotomy (tables 25.26) In comparison with the 
previous study, abnormal urea and electrolyte concentrations were not 
uncommon after thoracotomy (table 25). One patient was withdrawn from 
the study with some concern about renal function, preoperative values 
were normal, and no specific treatment was required.
A  high blood urea was commonly present after surgery, and the 
incidence of this was significantly greater in the ketorolac groups 
compared with the placebo group (P<0.05, Chi-square). In the high 
dose ketorolac group, the majority (17 out of 25) had high blood 
ureas 48 hours after operation, although only 2 also had high 
creatinine concentrations.
Hyperkalaemia occurred in 12 out of 75 patients, although this 
was not severe and did not require specific treatment. Of these 12 
patients, 4 were from the placebo group, and so high potassium 
concentrations did not appear to be associated only with ketorolac. 
The highest potassium was 5.7 mmol/litre, in a patient in the high 
dose ketorolac group.
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Placebo 10 mg 30 mg
Potassium 
>4.7 mmol/litre
Sodium
<132 mmol/litre
Urea
>6.6 mmol/litre
Creatinine 
>150 ^mol/litre
14 17
Table 25 Ketorolac and renal function. The number of patients with 
abnormal clinical chemistry results after thoracotomy. Placebo, 
ketorolac 10 mg, and ketorolac 30 mg groups.
Preoperative 48 h
Placebo
Sodium
Potassium
Urea
Creatinine
Ketorolac 10 mg 
Sodium
Potassium
Urea
Creatinine
Ketorolac 30 mg 
Sodium
Potassium
Urea
Creatinine
140(0.5) 
4.2(0.1) 
4.9(0.3) 
86(4)
139(0.6) 
4.1(0.1) 
5(0.4) 
87(3)
140(0.6) 
4.1(0.1) 
5(0.2) 
87(3)
136(0.7) 
4.4(0.1) 
6.1(0.4) 
100(7)
136(0.6) 
4.4(0.1) 
7.1(0.6) 
95(6)
136(0.6) 
4.4(0.1) 
7.9(0.5) 
110(7)
0.0000
0.2
0.002
0.03
0.001
0.03
0.001
0.15
0.0000
0.01
0.0000
0.002
Table 26 The effect of ketorolac on renal function after thoracotomy 
Plasma urea, creatinine, and electrolytes before, and after 48 hours 
Mean (SE), P: paired t-test.
Analysis of the changes in individual patient's values (table 26) 
demonstrates some differences between the placebo and the ketorolac 
groups. In the placebo group there was a significant fall in blood 
sodium, and a rise in urea and creatinine. Potassium concentrations 
rose, but this was not statistically significant (mean increase 0.2 
mmol/litre, 95%CI -0.1 to 0.5 mmol/litre). With ketorolac, sodium 
fell, and urea and creatinine were elevated, although the change in 
the latter was not statistically significant with ketorolac 10 mg.
The most notable difference with ketorolac was that there was a 
statistically significant increase in blood potassium, at 48 hours, 
in the low (0.2 mmol/litre, 95%CI 0.02 to 0.4 mmol/litre) and high 
(0.3 mmol/litre, 95%CI 0.1 to 0.6 mmol/litre) dose ketorolac groups.
6.2.3 Discussion Consideration of the results from the placebo 
groups involved in these two studies suggests that the patients 
having thoracotomy were more at risk of postoperative renal 
impairment. There was little apparent upset in blood values after 
cholecystectomy (tables 23, 24), but after thoracotomy urea, 
creatinine, and potassium rose (tables 25, 26). These differences 
could have been due to the different pathologies, age of the 
patients, and the extent of surgery. Cholecystectomy is performed in 
a relatively young population for a benign disorder. In contrast the 
patients in the thoracotomy group were older and having a more 
invasive operation for a malignant, wasting, disease. Another 
difference is that after thoracotomy intravenous fluids tend to be 
restricted to avoid pulmonary oedema which often occurs after 
manipulation of the lungs, and patients may be relatively dehydrated.
After cholecystectomy, ketorolac 30 mg did not produce abnormal 
changes in plasma urea, creatinine, or electrolytes. There was
-128-
therefore no evidence of any adverse renal effect of giving 
intramuscular ketorolac after this operation. There was some evidence 
from the cholecystectomy study that renal function may have been 
affected in some way by ketorolac. The ketorolac group differed from 
the consistent postoperative fall in urea, creatinine, and 
electrolytes seen in the control group, in that potassium and 
creatinine concentrations did not fall with ketorolac, and the falls 
in urea and sodium were much smaller. Without more detailed studies 
it is impossible to identify the reason for these differences. Fluid 
intake was not strictly controlled in this study and there was indeed 
evidence that ketorolac was associated with a shorter period of 
intravenous fluid supplementation (table 6). In the postoperative 
period renin, angiotensin, aldosterone, and vasopressin 
concentrations are elevated as part of the stress response to 
anaesthesia and surgery (121,123,124,125). Ketorolac could have 
interfered with these processes as renal prostaglandins are known to 
affect renin (132) and vasopressin (134).
After thoracotomy, ketorolac was associated with high urea 
concentrations and a rise in plasma potassium. Although these changes 
were present they did not produce any clinical problems, and 
hyperkalaemia occurred almost as often in the placebo group. NSAIDs 
may block the rise in renin produced by prostaglandins (132) and this 
could have impaired renal tubular potassium excretion in the 
ketorolac group. An initial report of unpublished observations of the 
effect of ketorolac on renal function after upper abdominal surgery 
has indicated that potassium excretion is impaired (216).
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6.2.4 Conclusion These observations suggest that ketorolac 
produces no renal impairment after cholecystectomy, but is associated 
with increased urea and rises in plasma potassium after thoracotomy 
for lung resection. Further studies of the effect of NSAIDs on renal 
function after major surgery are merited.
6.3 The effect of diclofenac on renal function and prostacyclin 
production after oesophagogastrectomy
6.3.1 Introduction In order to investigate further the effects of 
NSAIDs on renal function after surgery, diclofenac was used as 
ketorolac was not available for this purpose. It was our established 
practice to give intramuscular diclofenac in combination with local 
anaesthetics to provide analgesia after oesophagogastrectomies, 
performed via a thoracoabdominal approach. Maintenance of correct 
fluid balance is important in these cases, because fluid overload can 
precipitate pulmonary oedema after thoracotomy in these often 
malnutritioned patients. This was thought to be an appropriate 
clinical situation to investigate the effect of diclofenac on 
postoperative renal function, especially since fluid balance is 
routinely closely monitored after oesophagogastrectomy using central 
venous and urinary catheters. The effect of intramuscular diclofenac 
75 mg twelve hourly on fluid balance, renal function, and renal 
prostacyclin production was studied in patients having 
oesophagogastrectomy.
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6.3.2 Methods
Patient enrolment Twenty patients were enrolled. Exclusion 
criteria were as described in earlier studies in this thesis, and 
patients were also excluded if there was any evidence of renal 
insufficiency preoperatively on venous blood sampling and biochemical 
analysis, or a history of diuretic therapy or hypertension. All 
patients had oesophagogastrectomy for carcinoma, via a 
thoracoabdominal incision, and were operated on by the same thoracic 
surgeon.
Study Design A  double-blind, randomized study of the effect of 
diclofenac administration after major surgery. A  control group was 
included for comparison. Renal function and prostacyclin production 
was measured on the preoperative day, the day of surgery (day 1), and 
the following day (day 2). Patients were randomly allocated to be 
given five intramuscular injections of either diclofenac 75 mg 
(Voltarol, Geigy) or identical placebo, given twelve-hourly over 
forty-eight hours. The first intramuscular injection was given at 
induction of anaesthesia.
Anaesthetic technique and monitoring The general anaesthetic 
technique was standardized. Premedication was intramuscular 
papaveretum and atropine. Induction was with intravenous thiopentone 
or propofol, suxamethonium was used to facilitate tracheal 
intubation, the lungs were ventilated with nitrous oxide in oxygen 
with enflurane, and neuromuscular blockade maintained with 
atracurium. Fentanyl was given if indicated during surgery. At the 
end of the procedure the neuromuscular block was antagonised with 
neostigmine and atropine.
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Intercostal nerve blocks were performed on each patient before 
surgery (bupivacaine 0.5% with adrenaline). Postoperatively, all 
patients were given morphine by continuous intravenous infusion at a 
rate of 1 mg/hour, and supplementary opioid was available if pain 
relief was inadequate. During the study the patients were nursed in a 
high dependency unit.
In the operating theatre, central venous, arterial, and urinary 
catheters were inserted to allow routine monitoring and collection of 
blood and urine samples in the postoperative period.
Intravenous fluids An attempt was made to ensure that all 
subjects were given similar volumes of intravenous fluids. Surgical 
blood loss was replaced in the operating theatre with Hartmann's 
solution. Postoperatively, Hartmann's solution and dextrose 5% were 
infused alternately at a rate of 500 ml six hourly. Central venous 
pressure was maintained between 5 to 10 cm of water by the infusion 
of aliquots of plasma protein solution.
Measurement of renal function Before operation, venous blood 
samples were analysed for serum creatinine and electrolyte 
concentrations. Urine was collected on the day before surgery from 
the time of enrolment into the study. In the postoperative period, 
urine output was measured for forty-eight hours from the time of 
induction of anaesthesia.
Blood samples were taken on the day of surgery (day 1), and the 
next day (day 2), centrifuged at 2000 rpm, and the plasma removed. 
Aliquots of the twenty four hour urine collection were stored with 
the samples of plasma at -20°C for later analysis in a batch when the 
study was completed.
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Plasma and urine creatinine, electrolytes, and osmolality were 
examined in both groups over the three day study period (preoperative 
and first and second days after operation). Urine flow rate, urinary 
excretion of sodium and potassium, creatinine clearance, and free 
water clearance were calculated.
It was the normal practice of the surgical unit involved in this 
study to give intravenous frusemide if hourly urine volumes were 
persistently below 30 ml/hr, in order to avoid fluid overload. After 
discussion with the clinicians in charge of the unit, it was decided 
that it would not be possible to discard this practice during the 
study. In view of this, the prescription of diuretic (intravenous 
frusemide) in the postoperative period was also recorded as a 
reflection of physician concern about renal function. For analysis, 
the number of patients in each group receiving frusemide were 
compared.
Renal prostaglandin generation Renal production of prostacyclin, 
PGI2 , was measured before and after surgery using the urinary 
concentration of the stable metabolite 6-keto-PGFia (207,208) by the 
radioimmunoassay method described in Chapter 2.5.4. By measuring 
changes in prostaglandin levels in a serious of samples from 
individual patients, many nonspecific factors affecting 
radioimmunoassays were minimised (221).
Statistical analysis The two treatment groups were compared on 
the preoperative day and the first (day 1) and second (day 2) days 
after surgery. Changes in individuals from baseline were examined 
using paired t-tests, and between group comparisons were made using 
unpaired t-tests.
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6.3.3 Results
Subjects(table 27) Twenty patients were enrolled, and all had 
oesophagogastrectomy via a thoracoabdominal incision. The diclofenac 
and control groups were similar with respect to age, height, weight, 
sex, and surgical blood loss (P=0.6).
Preoperative day There was no statistical difference between the 
groups for plasma creatinine or electrolytes, urine output, 
electrolyte excretion, clearances, or 6-keto-PGFia production.
Plasma sodium, potassium, creatinine, and osmolality (table 28)
In the control group, there was a significant fall in plasma sodium 
concentration on day 1 (P=0.03, 95%CI -7,-0.04 mmol/litre), and 
plasma osmolality on days 1 and 2 (P=0.07 95% Cl -13,0.6 mosm/kg and 
P=0.03 95% Cl -18 to -2 mosm/kg). In the diclofenac group, plasma 
sodium fell on day 1 (P=0.05, 95% Cl -5 to 0 mmol/litre). There was 
no significant difference between the diclofenac and placebo groups 
in potassium concentrations at any time, but the diclofenac group did 
tend to have higher concentrations than the control group on the 
first postoperative day. On day 1, five of the diclofenac group had 
potassium concentrations in excess of the laboratory upper limit of 
normal (4.7 mmol/litre), and three of them were above 5 mmol/litre.
By comparison, only two patients in the control group had high 
potassium concentrations on day 1, and none were above 5 mmol/litre. 
Potassium concentrations in the diclofenac group returned towards 
normal by day 2.
Fluid balance (table 29) There was no significant difference in 
the amount of intravenous fluids given to the two groups on day 1 or 
day 2 (P=0.9, and 0.5 respectively). After fluid input and output,
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Diclofenac Control
Age (years) 
Height (cm) 
Weight (kg)
Sex (M/F)
Blood loss (ml)
65.2(9.1)
169.7(9.9)
63(17.2)
9/1
500(165)
69.8(9.5)
167.5(8.4)
68.9(15.7)
8/2
408(181)
Table 27 Diclofenac and renal function. Patient details (mean, SD) 
and operative blood loss (mean, SE).
Diclofenac Control P
Sodium (mmol/litre)
Preoperative 138(1) 138(2) 0.95
Day 1 136(1) 136(2) 0.9
Day 2 135(2) 135(2) 0.9
Potassium (mmol/litre)
Preoperative 4.4(0.2) 4.1(0.1) 0.2
Day 1 4.6(0.3) 4.2(0.2) 0.2
Day 2 4.3(0.2) 4.3(0.1) 0.8
Creatinine (/miol/litre)
Preoperative 89(5) 89(7) 0.95
Day 1 99(12) 106(13) 0.69
Day 2 104(16) 98(14) 0.77
Osmolality (mosm/kg)
Preoperative 282(2) 284(3) 0.7
Day 1 281(3) 278(4) 0.5
Day 2 279(4) 276(4) 0.58
Table 28 Diclofenac and renal function. Plasma sodium, potassium, 
creatinine, and osmolality. Mean (SE). P: unpaired t-test.
Diclofenac
Fluid balance(ml)
Day 1 1128(348)
Day 2 1569(275)
Urine output(ml/min) 
Preoperative 0.75(0.1)
Day 1 
Day 2
0.62(0.06) 
0.9(0.1)
Sodium excretion(/imol/min) 
Preoperative 63(14)
Day 1 
Day 2
43(9)
37(9)
Potassium excretion(/imol/min) 
Preoperative 22(3)
Day 1 
Day 2
49(6)
39(3)
Control
601(127)
1532(233)
0.89(0.1)
0.88(0.13)
0.98(0.16)
75(10)
78(8)
48(11)
19(4)
74(9)
41(7)
P
0.39
0.93
0.27
0.02
0.65
0.51
0.01
0.5
0.73
0.04
0.76
Table 29 The effect of diclofenac on fluid balance, urine output, and 
urinary sodium and potassium excretion. Mean (SE). P: unpaired 
t-test.
including blood loss, was considered the diclofenac group tended to 
have a higher positive fluid balance on the first postoperative day, 
although the difference was not statistically significant.
Urine output (table 29) Urine production was significantly lower 
in the diclofenac group on the first postoperative day (day 1) 
compared with the control group (P=0.02, 95%CI -0.5 to -0.06 ml/min). 
On the next day the two groups had similar urine outputs.
Sodium and potassium excretion (table 29) Urinary excretion of 
sodium was significantly less in the diclofenac group on day 1 
(P=0.01, 95% Cl -62 to -8 /imol/min). Potassium excretion increased in 
both groups in the postoperative period, but the rise was greater in 
the control group on day 1, so that potassium excretion was lower in 
the diclofenac group on that day (P=0.04, 95% Cl -49 to -1 ^mol/min).
Creatinine clearance (table 30) Baseline clearances were similar. 
In the control group there was a significant increase in creatinine 
clearance on the first postoperative day (P=0.02, 95% Cl 6 to 53 
ml/min), but the diclofenac group showed no change in creatinine 
clearance over the study period.
Free water clearance (table 30) A  negative value for free water 
clearance indicates retention of water. There was a significant 
difference between the groups on the first postoperative day when the 
control group retained more free water than the diclofenac group 
(P=0.04, 95%CI 0.01 to 0.8 ml/min)
Urinary 6-keto-PGF]n (figure 10. table 31) Urinary excretion of 
6-keto-PGFia increased markedly in the control group after surgery, 
with the highest concentrations on day 1. In contrast, the diclofenac 
group showed little change in urinary 6-keto-PGF^a over the two days. 
Consequently urinary 6-keto-PGFia excretion was significantly higher 
in the control group on days 1 and 2 (P=0.02 and 0.003 respectively).
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Diclofenac Control P
Creatinine clearance (ml/min)
Preoperative 61(10) 60(7) 0.97
Day 1 62(13) 89(14) 0.17
Day 2 62(11) 77(11) 0.38
Free water clearance (ml/min)
Preoperative -0.66(0.2) -0.07(0.2) 0.15
Day 1 -0.58(0.1) -0.98(0.2) 0.04
Day 2 -0.3(0.1) -0.2(0.3) 0.7
Table 30 The effect of diclofenac on creatinine and free water 
clearances. Mean (SE). P: unpaired t-test.
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Figure 10 Urinary 6-keto~PGF^a after 
oesophagogastrectomy. Mean (SE).
Diclofenac Control P
Preoperative 532(120) 338(78) 0.2
Day 1 587(85) 5111(1553) 0.02
Day 2 379(65) 1739(336) 0.003
Table 31 The effect of operation and diclofenac on the urinary 
excretion of 6-keto-PGF^a (pg/min). Mean (SE). P: unpaired t-test.
Frusemide Diuretic therapy was more often required in the 
diclofenac group since 9 of them were given frusemide during the 
study, but only 4 of the control group received the drug (P=0.02).
Adverse events (table 32) One patient in the diclofenac group was 
withdrawn from the study after eighteen hours because of concern 
about persistently low urine volumes (averaging 20 ml per hour). Two 
doses of diclofenac 75 mg had been given before the patient was 
withdrawn. Despite adequate fluid loading and frusemide 
administration, intravenous dopamine was required to promote an 
acceptable urine flow rate. Following withdrawal of diclofenac and 
commencement of dopamine, renal function improved and the patient 
recovered completely. Blood analysis revealed a marked rise in 
creatinine and potassium concentration on day 1. Plasma potassium on 
day 1 was particularly high at 5.4 mmol/litre (laboratory normal 
upper limit 4.7 mmol/litre). It should also be noted that, although 
preoperative creatinine was within normal limits (55 to 150 
/imol/litre), this patient had a low preoperative creatinine clearance 
(45 ml/min) and that this fell by almost half on the first 
postoperative day. Urinary 6-keto-PGFia increased in this patient 
after diclofenac was withdrawn.
6.3.4 Discussion
Renal prostaglandin generation Urinary 6-keto-PGF]^a production 
increased markedly in the postoperative period in the control group, 
whereas there was no change in the diclofenac group (figure 10, table 
31). Urinary 6-keto-PGF^a is an accepted indicator of renal 
prostacyclin production (207,208,209). To the author's knowledge this 
is the first report of such a rise in renal prostacyclin production 
after surgery in humans and of the effect of diclofenac.
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Preoperative Day 1 Day 2
Sodium 138 138 136
(mmol/litre)
Potassium 4.6 5.4 4.5
(mmol/litre)
Creatinine 101 158 145
(^miol/litre)
Osmolality 278 292 289
(mosm/kg)
Creatinine 45 25 26
clearance(ml/min)
6-keto-PGFia 262 725 1455
Table 32 Details of the patient withdrawn from the diclofenac group 
on day 1.
Renal prostaglandins are thought to be act as local vasodilators 
which maintain function in the presence of high concentrations of 
circulating vasoconstrictor hormones, when blood flow can become 
'prostaglandin dependent' (90,108). On the basis of the results of 
this study it may be that renal prostaglandins are important after 
surgery. Renal prostacyclin production peaked on the first 
postoperative day, perhaps indicating that this effect is most 
important in the immediate postoperative period.
As there must be significant tissue damage and disruption during 
and after oesophagogastrectomy, it should be established that the 
urinary 6-keto-PGF^a measured in this study did indeed represent 
renal, and not systemic, prostacyclin generation. There is no 
published work concerning the effect of anaesthesia and surgery on 
urinary metabolites, but studies have been reported using plasma 6- 
keto-PGF^a which may give insight into the systemic production of 
prostacyclin after operation. Minor surgery does not increase plasma 
6-keto-PGFia whether using halothane, enflurane (222), or spinal 
anaesthesia (223). Plasma 6-keto-PGFia is elevated upon the surgical 
incision of laparotomy, but falls again within forty minutes in 
elderly patients (224). Prostacyclin and TxB2 release increases 
during abdominal aortic surgery, an effect prevented by ibuprofen 
(225). These studies indicate that systemic prostacyclin production 
is not greatly increased after surgery. The rise in urinary 6-keto- 
PGF^a observed in this thesis may therefore truly reflect an increase 
in renal prostacyclin production after major surgery. To further 
investigate this, it would be useful to observe after surgery both 
urinary 2,3 dinor 6-keto-PGF^a and 6-keto~PGF^a to represent systemic 
and renal production of prostacyclin, as performed in other clinical 
studies (209).
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Renal function In this study, diclofenac therapy was associated 
with a significant reduction in urinary output and sodium and 
potassium excretion on the first postoperative day when compared with 
the control group. On the second day, there was no difference between 
the groups (table 29). Renal prostaglandins increase urinary sodium 
excretion (129,131), and by inhibiting this diclofenac could produce 
sodium retention.
Potassium excretion increased in both groups after surgery, but 
this effect was diminished by diclofenac. Prostacyclin stimulates 
renin release in man (132), and, by preventing the resultant 
aldosterone effect, diclofenac could have impaired potassium 
excretion. Presumably in the postoperative period there is a 
significant potassium load presented to the kidneys which has to be 
dealt with to avoid hyperkalaemia. In this study, diclofenac tended 
to be associated with hyperkalaemia on the first day after surgery, 
although preoperative values were also slightly higher than in the 
control group (table 28).
There was no evidence of a fall in GFR after surgery with the 
NSAID, although the rise in creatinine clearance seen in the control 
group was not present in the diclofenac group (table 30). Creatinine 
clearance may not be a reliable estimate of GFR after surgery when 
plasma creatinine could be changing as a result of muscle damage. 
Inulin clearance studies may be more useful.
Because NSAIDs potentiate vasopressin (108,115,116,134), it may 
have been expected that the diclofenac group would retain more water, 
but in fact the control group conserved more free water on the first 
postoperative day (table 30). This was reflected in the tendency for 
plasma osmolality to decrease in the control group (table 28). Other 
factors, including pain and morphine administration, may be involved
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as both are known to increase vasopressin release. The control group 
did require more morphine 62(5.3) mg, than the diclofenac group 
49(7.7) mg, although the difference was not statistically significant 
(P=0.2, 95% Cl -7, 32 mg), but pain assessments were not made. In 
this respect there is evidence that vasopressin is involved in an 
non-opioid analgesic system controlled by the hypothalamic 
paraventricular nucleus (226), although the true role of vasopressin 
in this system is under scrutiny (227).
Frusemide therapy was required more often in the diclofenac 
group. Although it would have been desirable to control the 
administration of diuretics during the study, it was not possible to 
do so in practice. If diuretics had not been given, the differences 
between the groups in urine and electrolyte excretion may have been 
even greater.
The patient withdrawn from the study did appear to have a severe 
but reversible impairment of renal function, with hyperkalaemia 
(table 32). This patient, despite having a normal preoperative plasma 
creatinine of 101 /imol/litre, was subsequently discovered to have a 
low creatinine clearance of 45 ml/min; an investigation not routinely 
performed before surgery. The deterioration in renal function 
observed in this patient may well have resulted from diclofenac, and 
is similar to the effect of other NSAIDs given to patients with 
asymptomatic renal failure (110). This emphasises the importance of 
monitoring renal function when NSAIDs are given to patients at risk 
of adverse effects.
The patients in this study were elderly and had major surgery for 
a debilitating disease. It is likely that this group would be 
susceptible to NSAID induced renal toxicity (111), and this may be 
less of a problem in other surgical patients.
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It would be interesting to pursue these findings in further 
studies. Para-amino hippuric acid and inulin clearances to measure 
renal plasma flow and GFR would be useful. Assays of renin and 
vasopressin would give more information concerning renal potassium 
and water handling. The effect of opioids and pain on vasopressin 
should also be addressed, and diuretic therapy controlled more 
stringently.
6.3.5 Conclusion A  postoperative increase in renal prostacyclin 
production was demonstrated which was suppressed by diclofenac. The 
reduction of urine output, potassium and sodium excretion, and the 
tendency to hyperkalaemia observed with diclofenac was present only 
in the immediate postoperative period when renal prostaglandin 
production was maximal. One patient given diclofenac had marked renal 
impairment. This may confirm previous suggestions that renal function 
is dependent upon prostaglandins immediately after anaesthesia and 
surgery (90,126), and that this can be adversely affected by NSAID 
administration. This work emphasises that if NSAIDs are used after 
major surgery, urinary output and plasma potassium should be 
monitored. NSAIDs should be avoided in surgical patients when there 
is a history of pre-existing renal impairment, congestive cardiac 
failure, liver cirrhosis, or hypovolaemia (90).
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CHAPTER 7
NSAIDs AND POSTOPERATIVE PAIN RELIEF
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7.1 NSAIDs as postoperative analgesics
Conventional postoperative pain relief based on intramuscular 
opioids may be unsatisfactory because of under administration 
resulting from about side-effects and practical difficulties in 
dispensing controlled drugs (28,30). The potential offered by the 
NSAIDs was that they were effective and safe analgesics which could 
be given without concern of side-effects. The studies in this thesis 
have examined these claims to efficacy and safety.
Potency In common with previous studies of NSAIDs, the 
investigations performed indicate that ketorolac is not an adequate 
analgesic for the relief of the severe pain present immediately after 
abdominal surgery. Later in the postoperative period, when the pain 
was less, ketorolac was as good as morphine.
This may suggest that ketorolac and diclofenac should not be the 
sole agents used to treat severe pain. The appropriate use of these 
drugs may be for the relief of mild to moderate pain either after 
minor surgery, or on the day after major surgery.
There is a need for clinical studies comparing regimens of 
ketorolac and diclofenac. Diclofenac 75 mg can only be given twice 
daily for safety reasons, although it has an elimination half life of 
only one to two hours (45). The studies presented in this thesis 
confirm that ketorolac 30 mg, with a longer half life of four to six 
hours, can be given four times a day with no adverse effects.
Morphine sparing effect After thoracotomy, little benefit was 
found in combining intramuscular ketorolac with intravenous, patient 
controlled, morphine. This was in contrast with previous studies 
where NSAIDs given in this way produced definite benefits (38,84,41). 
Various reasons for this difference have been discussed in this
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thesis, but it may be that the previously reported beneficial, 
morphine sparing, effect of NSAIDs may not be obvious in every 
clinical situation.
Route of administration Diclofenac produces muscle damage on 
injection (64), it is not approved for intravenous use, and as a 
result rectal administration is becoming popular. Ketorolac will be 
available initially for intramuscular, and possibly intravenous use, 
with an oral preparation to follow later. Intramuscular ketorolac has 
been well tolerated in the studies in this thesis, and it is probable 
that this will be the main route of administration. The availability 
of oral preparations of diclofenac and ketorolac means that 
administration could be continued by tablet once parenteral therapy 
is no longer required.
Day stay surgery The NSAIDs may be ideal analgesics for day case 
surgery when patients are discharged home within a few hours of 
having relatively minor operations. Although only mild to moderate 
pain should be expected after such surgery, it is often difficult to 
provide effective relief of this because of the need to avoid opioids 
with their depressant side-effects and potential for abuse. Ketorolac 
and diclofenac could safely be given during surgery by injection, 
and, if necessary, continued afterwards orally when the patient 
leaves hospital. As ketorolac and diclofenac are not controlled 
drugs, it is possible to supply them to patients for use at home.
7.2 NSAID side-effects
Administration of NSAIDs should be avoided in certain patients 
and operations because of potential adverse effects. This may 
restrict the usefulness of ketorolac and diclofenac.
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Platelet function Ketorolac and diclofenac have been shown in 
this thesis to affect platelet function within one hour of 
intramuscular administration. Skin bleeding time was prolonged, 
although values were not above the upper limit of normal. There was 
no evidence that this increased operative blood loss, even in 
patients who had also been given subcutaneous heparin. Although these 
results are reassuring, it may be prudent to avoid or delay NSAID 
administration when bleeding is expected to be excessive or difficult 
to control, as abnormal bleeding can occur after aspirin even when 
skin bleeding time is normal (98). Ketorolac and dextran-70 did not 
produce any serious interaction in volunteers, but a degree of 
caution should be exercised in giving this combination to patients 
until clinical experience of NSAIDs during surgery has expanded.
The anti-platelet effect may also mean that ketorolac and 
diclofenac should not be given before subarachnoid or extradural 
blocks are performed as excessive bleeding from trauma to extradural 
vessels could lead to haematoma formation and have serious 
consequences (228,106). It may be prudent to delay administration of 
the NSAID until the block has been performed. If aspirin or an NSAID 
has already been given, a skin bleeding time estimation may be useful 
(200), and should be less than 10 minutes (228).
Gastrointestinal system A history of peptic ulceration should be 
a contraindication to the use of these drugs during surgery. This 
will mean that a considerable number of surgical patients will be 
excluded from having these drugs (table 1). The recognition of NSAID 
induced enteropathy means that a history of inflammatory bowel 
disease should also be a contraindication, and this should include 
patients operated on for Crohn's disease and ulcerative colitis.
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It is not clear whether a short postoperative course of ketorolac 
or diclofenac will induce gastrointestinal changes in previously 
normal patients. In this thesis, dyspepsia was not a common complaint 
when ketorolac was given for two days after cholecystectomy or 
thoracotomy. Further studies of the effect of these drugs on the 
gastrointestinal system, including permeability studies, are required 
before general administration can be recommended.
Renal function NSAIDs should not be used when there is any pre­
existing renal impairment, or in medical conditions where renal 
perfusion may be dependent upon prostaglandins including congestive 
cardiac failure, hypovolaemia, or hepatic cirrhosis with ascites 
(90,31).
This thesis also confirms earlier suggestions that renal function 
is dependent on prostaglandins after surgery (90,126), and that 
NSAIDs can have adverse effects even in the absence of pre-existing 
renal dysfunction. After major surgery, a normal postoperative 
increase in renal prostacyclin generation was described which was 
suppressed by diclofenac. Diclofenac was associated with reduced 
urine flow rate and potassium and sodium excretion and a tendency to 
hyperkalaemia. One patient had marked renal impairment with 
diclofenac. It was not possible to study ketorolac in detail, but it 
did not obviously impair renal function after cholecystectomy, 
whereas after more major surgery, thoracotomy, there was some 
evidence of an adverse effect.
If NSAIDs are used after surgery, then renal function should be 
monitored closely by observing the rate of urine production and serum 
potassium concentrations. NSAIDs should not be used in surgical 
patients who have pre-existing renal problems.
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Aspirin sensitive asthma NSAIDs should be avoided in patients 
with asthma and nasal polyps or chronic rhinitis as severe 
bronchospasm may be precipitated (159). It may indeed be prudent to 
avoid NSAIDs in any asthmatic patient, as a significant proportion 
will be affected and severe bronchospasm can be produced (164). The 
ability of an NSAID to produce bronchospasm is related to potency as 
a cyclo-oxygenase inhibitor, and ketorolac and diclofenac are much 
more potent than aspirin. It may therefore be advisable to avoid 
ketorolac and diclofenac in asthmatics even when there is a history 
of aspirin ingestion with no effect.
Other side effects No unusual adverse effects, including liver 
toxicity, blood dyscrasias, or anaphylactic reactions were 
encountered when ketorolac and diclofenac were given during the 
studies comprising this thesis. The absence of such problems is not 
conclusive as the incidence of these problems is known to be low 
(89,171). There were no nervous system effects, although headache, 
dizziness, and drowsiness have been reported after ketorolac (57,67). 
Further clinical experience using these drugs in surgical patients is 
required to assess the incidence and importance of such adverse 
effects.
7.3 NSAIDs and the prevention of pain after surgery
Investigations of the pathophysiology of acute pain have 
suggested that afferent pathways can become sensitised by noxious 
stimuli (229). Consequently, emphasis is changing to the prevention 
of pain by pretreatment with analgesics before surgery (230,231). 
Impressive results have been produced using balanced analgesia of 
opioids, local anaesthetics and NSAIDs to prevent postoperative pain, 
even after major surgery (232). With this shift in emphasis from the
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treatment to the prevention of pain, it is likely that ketorolac and 
diclofenac will be increasingly used prophylactically, as part of 
analgesic techniques also including local anaesthetics and opioids.
7.4 Prostaglandin and thromboxane production after surgery
Little is known of the effect of anaesthesia and surgery on 
prostaglandin physiology. Recent animal work has found that 
thiopentone and ether anaesthesia both reduce the density of 
prostaglandin receptors in the liver, and the comment was made that:
"...it might be generally acceptable that5some prostanoids could 
play an important role during anaesthesia through their action on 
the cardiovascular system, or their involvement in haemostasis." 
(233)
Venous blood TxB2 production is increased for up to a day after 
surgery (222,223,40). As thromboxanes are powerful platelet 
aggregators and vasoconstrictors, this may represent a risk factor 
for cardiovascular and thromboembolic complications in susceptible 
patients in the postoperative period (222). By inhibiting thromboxane 
production and platelet aggregation, ketorolac and diclofenac could 
have the additional benefit of reducing such cardiovascular 
complications, including the common problem of thromboembolism 
(105,106).
Unfortunately, NSAIDs also block the production of prostacyclin 
(99), which is a vasodilator, prevents platelet aggregation, and may 
be important in protecting the myocardium against sudden vessel 
occlusion (173). Aspirin may be more effective at preventing 
cardiovascular problems after surgery, as it inhibits platelet
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thromboxane longer than endothelial prostacyclin (99), which is the 
basis of low dose therapy in medical practice. Conversely, 
paracetamol blocks prostacyclin, but not thromboxane (99), an effect 
which could be considered harmful. Such considerations may be also of 
importance after vascular surgery when vessel patency may be affected 
by platelet activity.
If prostaglandins and thromboxanes play an important role after 
surgery, then NSAIDs could have diverse effects, both beneficial and 
harmful, which have as yet been disregarded. The effect of 
anaesthesia and surgery on arachidonic acid metabolism, and of the 
consequences of NSAID administration, offers a vast and fascinating 
area for further research.
7.5 Conclusion
NSAIDs may be adequate for the relief of pain of moderate 
intensity after operation, and it is probable that ketorolac and 
diclofenac will be commonly used. NSAIDs potentially can have severe 
adverse actions, and the safe use of ketorolac and diclofenac in 
surgical patients will be dependent on the proper recognition of 
their effects and side-effects.
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